{"study_id": 104739, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were examining the activity and safety of combining chemotherapy with ponatinib for treating Philadelphia chromosome-positive acute lymphoblastic leukaemia, not specifically evaluating Alanine.", "results_summary": "The study found that the combination of chemotherapy with ponatinib was effective in achieving early sustained remissions, with a 2-year event-free survival rate of 81%. Adverse effects included infections, elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase), thrombotic events, and myocardial infarction.", "population_specificity": "Adult patients with previously untreated Philadelphia chromosome-positive acute lymphoblastic leukaemia or those who had received fewer than two courses of previous chemotherapy.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Not specified for Alanine.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:26.460651+00:00"}
{"study_id": 104743, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to evaluate the effect of a multidisciplinary intervention program on hepatic fat fraction and cardiometabolic risk factors in overweight or obese children, including the measurement of alanine aminotransferase as a secondary outcome.", "results_summary": "The abstract does not report specific results regarding alanine aminotransferase or Alanine's effects, as it describes a planned study rather than completed findings.", "population_specificity": "Overweight or obese children aged 9-11 years.", "effective_dosage": "Not available", "study_duration": "22 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:28.612184+00:00"}
{"study_id": 104742, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study assessed the safety and clinical outcomes of ipilimumab in Japanese patients with unresectable stage III or IV melanoma, not specifically Alanine.", "results_summary": "The study reported increased alanine aminotransferase (ALT) as a drug-related adverse event in 3 patients (15%), but the focus was on ipilimumab's safety and efficacy, not Alanine's effects.", "population_specificity": "Japanese patients with unresectable stage III or IV melanoma.", "effective_dosage": "Not applicable (study focused on ipilimumab, not Alanine).", "study_duration": "Four doses of ipilimumab administered every 3 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:28.923792+00:00"}
{"study_id": 104744, "supplement_id": 863, "safety_score": "20", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the safety and efficacy of ipilimumab plus dacarbazine in Japanese patients with melanoma, focusing on adverse events including alanine aminotransferase increases.", "results_summary": "The study found frequent adverse events, particularly liver toxicities (80% of patients), leading to high discontinuation rates (60%). Efficacy was limited, with a 13% response rate and 40% disease control rate.", "population_specificity": "Japanese patients with unresectable stage III or IV melanoma.", "effective_dosage": "Ipilimumab 10 mg/kg plus dacarbazine 850 mg/m\u00b2 every 3 weeks for four doses, followed by dacarbazine alone and then ipilimumab every 12 weeks.", "study_duration": "Until disease progression or intolerable toxicity (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.484280+00:00"}
{"study_id": 104741, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 78, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effectiveness of adefovir dipivoxil alone and in combination with \u03b1-2b interferon in treating HBeAg-negative and HBeAg-positive chronic hepatitis B, respectively, by measuring ALT normalization, HBV-DNA negative conversion, and HBeAg/HBeAb sero-conversion rates.", "results_summary": "The study found that adefovir dipivoxil combined with \u03b1-2b interferon significantly improved ALT normalization and HBV-DNA negative conversion rates over time, with higher efficacy compared to adefovir dipivoxil alone, particularly in HBeAg-positive patients.", "population_specificity": "Adult patients with HBeAg-negative or HBeAg-positive chronic hepatitis B (102 cases).", "effective_dosage": "10mg adefovir dipivoxil capsules once daily; 5 million U Recombinant Human Interferon \u03b1-2b injected intramuscularly every other day (for the treatment group).", "study_duration": "18 months (with key outcomes measured at 6 and 18 months).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:30.965302+00:00"}
{"study_id": 104746, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to validate the efficacy and resistance outcomes of telbivudine (LdT) treatment in chronic hepatitis B (CHB) patients with favorable predictors, comparing real-world clinical data to the GLOBE study.", "results_summary": "The study found that CHB patients with favorable baseline characteristics and on-treatment response to LdT achieved high rates of virologic and biochemical response, with low genotypic resistance. PCR negativity at week 24 was a key predictor of treatment success.", "population_specificity": "Chronic hepatitis B (CHB) patients, both HBeAg-positive and HBeAg-negative.", "effective_dosage": "Not specified", "study_duration": "2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:31.536332+00:00"}
{"study_id": 104745, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop a pre-endoscopic risk score (C-WATCH) for acute upper gastrointestinal bleeding (UGIB), including variceal bleeding, to identify high-risk patients requiring urgent clinical management, with alanine-aminotransferase as one of the significant predictors.", "results_summary": "The study identified alanine-aminotransferase as a significant predictor for complications (recurrent bleeding, need for intervention, or death within 30 days) in acute UGIB. The derived C-WATCH score effectively stratified patients into low- and high-risk groups, with high-risk patients showing a 38.7% complication rate.", "population_specificity": "586 patients with acute UGIB from the emergency department and inpatient services at the University Hospital of Cologne, plus a validation cohort of 322 patients.", "effective_dosage": "Not available", "study_duration": "Data collected over a 2-year period (01/2007-12/2008) with validation in 2009.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:32.007526+00:00"}
{"study_id": 104747, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to determine the maximum tolerated dose (MTD) and pharmacokinetics of volasertib combined with nintedanib in patients with advanced solid tumors, not specifically focused on Alanine.", "results_summary": "The study reported dose-limiting toxicities involving increased alanine aminotransferase (ALT) in some patients, but the focus was on the combination therapy's safety and efficacy, not Alanine itself.", "population_specificity": "Patients with advanced metastatic solid tumors following failure of conventional treatment.", "effective_dosage": "Not applicable (study focused on volasertib and nintedanib, not Alanine).", "study_duration": "First cycle: 28 days; subsequent cycles: 21 days.", "interactions": "None mentioned (regarding Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.141420+00:00"}
{"study_id": 104748, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers investigated whether genetic variation in the bitter taste receptor gene TAS2R38 (specifically the A49P variant, involving alanine to proline substitution) influenced children's rejection of liquid medications due to taste.", "results_summary": "Children with at least one sensitive TAS2R38 allele (AP or PP genotype) were more likely to reject liquid medications due to taste compared to those without a taster allele (AA genotype). Mothers' reports of their children's medication problems were concordant with the children's own reports.", "population_specificity": "172 children aged 3 to 10 years and their mothers (N=130).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:35.150076+00:00"}
{"study_id": 104749, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to investigate the occurrence and clinical characteristics of acute pancreatitis associated with acute hepatitis E infection.", "results_summary": "Of 790 patients with acute pancreatitis, 16 (2.1%) had hepatitis E as the sole cause. The pancreatitis was mild in 10 and severe in 6 patients, with complications including intra-abdominal collections, acute renal failure, and acute lung injury. The prognosis was generally good, with no need for surgical or other interventions.", "population_specificity": "Patients admitted with acute pancreatitis and diagnosed with acute hepatitis E (median age 25 years, predominantly male).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:36.961305+00:00"}
{"study_id": 104750, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of a chemotherapy-free regimen (ATRA and arsenic trioxide) versus a standard chemotherapy-based regimen (ATRA and idarubicin) in treating acute promyelocytic leukaemia.", "results_summary": "The study found that ATRA and arsenic trioxide had a high cure rate, less relapse, and similar survival compared to ATRA and idarubicin, with lower incidence of liver toxicity but no significant difference in quality of life.", "population_specificity": "Patients aged \u226516 years with acute promyelocytic leukaemia confirmed by PML-RARA transcript, without significant cardiac or pulmonary comorbidities or active malignancy, and not pregnant or breastfeeding.", "effective_dosage": "Not Assessed", "study_duration": "Treatment duration varied by regimen, with follow-up until remission or day 60 for ATRA, and additional courses for arsenic trioxide or idarubicin.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:38.695602+00:00"}
{"study_id": 104751, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of pegylated interferon (IFN)-\u03b1-2a versus conventional IFN-\u03b1-2a on intrahepatic cccDNA and other parameters in chronic hepatitis B patients.", "results_summary": "Both treatments significantly reduced intrahepatic cccDNA, HBV DNA levels, and improved histologic and biochemical parameters, with peg IFN-\u03b1-2a showing greater reductions.", "population_specificity": "HBeAg-positive chronic hepatitis B patients (n=76).", "effective_dosage": "Not specified for Alanine (study focused on IFN-\u03b1-2a and peg IFN-\u03b1-2a).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:39.559832+00:00"}
{"study_id": 104752, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to assess the effects of PD-0360324 on alanine/aspartate aminotransferases (ALT/AST) levels in patients with cutaneous lupus erythematosus (CLE).", "results_summary": "The study found statistically significant changes in ALT and AST levels between active treatment and placebo groups, but no clinical improvement in CLE symptoms was observed. Alanine-related outcomes were secondary and not linked to therapeutic efficacy.", "population_specificity": "Patients with active subacute CLE or discoid lupus erythematosus.", "effective_dosage": "100 or 150 mg PD-0360324 every 2 weeks.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:40.048628+00:00"}
{"study_id": 104754, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to summarize the clinical efficacy and safety outcomes of teriflunomide, including its effects on alanine aminotransferase levels, in patients with relapsing forms of multiple sclerosis.", "results_summary": "The study found that teriflunomide treatment was associated with an increase in alanine aminotransferase levels as an adverse event, occurring in \u22652% of patients. However, the overall safety profile included routine monitoring to manage potential risks.", "population_specificity": "Patients with relapsing forms of multiple sclerosis (RMS).", "effective_dosage": "14 mg and 7 mg once daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:41.182122+00:00"}
{"study_id": 104755, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to characterize the HBV genotypes, clinical profiles, and laboratory findings (including alanine aminotransferase levels) in children with chronic hepatitis B in the US and Canada.", "results_summary": "The study found that children with HBV genotypes B or C had lower frequencies of elevated alanine aminotransferase values (43% and 57%) compared to other genotypes, suggesting differences in liver inflammation markers by genotype.", "population_specificity": "Children aged 1.0-17.8 years with chronic hepatitis B, predominantly of Asian origin (78%) and international birth (97%).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.051485+00:00"}
{"study_id": 104756, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 68, "study_goal": "The researchers aimed to evaluate the effectiveness of hepatic fat quantification MR in monitoring treatment effects, including changes in alanine aminotransferase levels, in pediatric NASH patients.", "results_summary": "The study found that alanine aminotransferase levels significantly decreased in the compliant group (-110.7 IU/L) compared to the non-compliant group (-10.6 IU/L), indicating improved liver function with treatment adherence.", "population_specificity": "Pediatric patients (mean age 12 \u00b1 2.3 years) with nonalcoholic steatohepatitis (NASH).", "effective_dosage": "Not specified", "study_duration": "1-year follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:45.385976+00:00"}
{"study_id": 104757, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 95, "study_goal": "The researchers aimed to evaluate the safety and effectiveness of enzyme-replacement therapy with sebelipase alfa in normalizing alanine aminotransferase levels and improving lipid metabolism in patients with lysosomal acid lipase deficiency.", "results_summary": "Sebelipase alfa therapy significantly normalized alanine aminotransferase levels (31% vs. 7% in placebo) and improved lipid profiles and hepatic fat content, with adverse events being mild and unrelated to treatment.", "population_specificity": "Children and adults with lysosomal acid lipase deficiency.", "effective_dosage": "1 mg per kilogram of body weight intravenously every other week.", "study_duration": "20 weeks (double-blind phase), followed by open-label treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:46.598742+00:00"}
{"study_id": 104758, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the prognostic value of hsCRP in predicting the short-term progression from NAFLD to NASH in NIDDM patients, not specifically focusing on Alanine.", "results_summary": "The study found that higher baseline serum hsCRP levels were significantly associated with increased risk of progression from NAFLD to NASH in NIDDM patients, with OR values ranging from 1.000 to 32.131 across quartiles. Alanine aminotransferase (ALT) was measured as a baseline variable but not as a primary focus of the study.", "population_specificity": "1128 NIDDM patients with a definite diagnosis of NAFLD.", "effective_dosage": "Not specified", "study_duration": "One year follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:47.671658+00:00"}
{"study_id": 104759, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the occurrence of rhabdomyolysis in Ebola virus disease (EVD) patients by comparing creatine kinase (CK) levels between EVD and non-EVD patients.", "results_summary": "High CK levels and rhabdomyolysis were more frequent in EVD patients than in non-EVD patients, with 36% of EVD patients showing CK levels >5000 U/L. Fatal outcomes in EVD patients were associated with higher creatinine, bilirubin, international normalized ratio, and viral load.", "population_specificity": "38 patients admitted to an Ebola treatment center from January to April 2015, including those with and without confirmed EVD.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:48.665936+00:00"}
{"study_id": 104760, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the efficacy and safety of XELOX plus bevacizumab in Japanese metastatic colorectal cancer patients, including elderly individuals, but did not specifically focus on Alanine.", "results_summary": "The study found that XELOX plus bevacizumab showed a promising response rate (52.2%) and acceptable tolerability in Japanese metastatic colorectal cancer patients, with common adverse events including alanine aminotransferase elevation (21.3%). However, the study did not specifically assess Alanine's effects.", "population_specificity": "Japanese metastatic colorectal cancer patients, including elderly individuals (median age 69 years, range 38-81 years).", "effective_dosage": "Not applicable (study did not focus on Alanine).", "study_duration": "Treatment was administered every 3 weeks, but the total duration is not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:49.451989+00:00"}
{"study_id": 104761, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether tiopronin could prevent hepatotoxicity induced by sorafenib and antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma (HCC).", "results_summary": "Tiopronin significantly reduced abnormal liver function markers (ALT, AST, TBIL, ALB), lowered course discontinuations and dose reductions, and improved disease control rates compared to the control group. No difference was observed in HBV DNA levels.", "population_specificity": "82 patients (median age 50 years; 71% male) with advanced HBV-related HCC treated with sorafenib and antiviral therapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:49.579368+00:00"}
{"study_id": 104762, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the efficacy and safety of n-3 polyunsaturated fatty acids (PUFA) treatment in obese children with nonalcoholic fatty liver disease (NAFLD), focusing on improvements in liver steatosis and transaminase levels.", "results_summary": "The study found that PUFA treatment significantly reduced the prevalence of liver steatosis and elevated ALT and AST levels in obese children with NAFLD, with 67.8% of the PUFA group showing improvement. The placebo group also showed some improvement, but the effects were less pronounced.", "population_specificity": "Obese adolescents (BMI >95th percentile for age and sex) aged 9-17 years with NAFLD.", "effective_dosage": "1000 mg of PUFA once daily.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:54.570309+00:00"}
{"study_id": 104764, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were evaluating the efficacy and safety of lenvatinib in patients with advanced medullary thyroid carcinoma (MTC), not specifically studying alanine.", "results_summary": "The study found that lenvatinib had a 36% objective response rate and an 80% disease control rate in MTC patients, with common adverse events including increased alanine aminotransferase levels (5%).", "population_specificity": "Patients with unresectable progressive medullary thyroid carcinoma (MTC).", "effective_dosage": "24 mg daily in 28-day cycles.", "study_duration": "Until disease progression, unmanageable toxicity, withdrawal, or death.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:54.635581+00:00"}
{"study_id": 104763, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the efficacy of inpatient versus ambulatory intensive lifestyle interventions in treating NAFLD in severely obese children, with serum alanine aminotransferase (ALT) as a primary outcome measure.", "results_summary": "The study found that intensive lifestyle interventions (inpatient and ambulatory) led to ALT normalization in 41% and 33% of participants, respectively, compared to 6% in usual care, but only a minority of patients achieved reversal of NAFLD. No baseline characteristics consistently predicted treatment response.", "population_specificity": "Severely obese non-diabetic children (mean age 14.7 years, BMI-z-score 3.5) with liver steatosis.", "effective_dosage": "Not specified (lifestyle intervention, not alanine supplementation).", "study_duration": "6 months (with follow-up at 1.5 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:55.019175+00:00"}
{"study_id": 104765, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to assess the safety and pharmacokinetics/pharmacodynamics of CSL112, a formulation containing human apolipoprotein A-I, in patients with stable atherosclerotic disease.", "results_summary": "CSL112 was well tolerated with no clinically significant elevations in alanine aminotransferase or aspartate aminotransferase. It rapidly and dose-dependently increased apoA-I levels and enhanced cholesterol efflux capacity.", "population_specificity": "Patients with stable atherosclerotic disease", "effective_dosage": "1.7 g, 3.4 g, or 6.8 g (single dose)", "study_duration": "Single 2-hour infusion", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:56.415254+00:00"}
{"study_id": 104766, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the therapeutic effects of probiotics (Lactobacillus subtilis/Streptococcus faecium) on liver function and gut-derived LPS in patients with alcoholic hepatitis.", "results_summary": "Probiotics improved albumin levels and reduced TNF-\u03b1 and E. coli colony-forming units, while placebo showed increased LPS levels. Probiotics were associated with restoration of bowel flora and LPS improvement.", "population_specificity": "Patients with alcoholic hepatitis (117 participants, 60 probiotics, 57 placebo).", "effective_dosage": "1500 mg/day of cultured Lactobacillus subtilis/Streptococcus faecium.", "study_duration": "7 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.118188+00:00"}
{"study_id": 104768, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the effects of dronabinol on metabolic parameters, including alanine aminotransferase, during long-term dosing, hypothesizing no significant impact.", "results_summary": "The study found no significant changes in metabolic parameters, including alanine aminotransferase, after 28 days of dronabinol treatment, with some favorable but non-significant trends observed.", "population_specificity": "Adults aged 18-75 with esophageal hypersensitivity and recurrent chest pain, excluding those with cardiac disease, prior pain medication use, or significant comorbidities.", "effective_dosage": "5 mg twice daily", "study_duration": "28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:57.865150+00:00"}
{"study_id": 104767, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 45, "study_goal": "The researchers aimed to assess the association between itraconazole therapy and severe hepatotoxicity, including elevated alanine transaminase levels, in a patient with histoplasmosis.", "results_summary": "The study reported a case of severe hepatotoxicity (alanine transaminase >15\u00d7 upper limit normal) after 6 months of itraconazole therapy, with therapeutic serum concentrations (5 mg/mL). Causality assessments indicated a probable to highly probable association with itraconazole exposure.", "population_specificity": "A single patient with histoplasmosis receiving itraconazole therapy.", "effective_dosage": "Therapeutic serum concentration of 5 mg/mL (specific dosage not provided).", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:58.000902+00:00"}
{"study_id": 104753, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers reviewed structural features and protein-inhibitor interactions of trypsin-like serine proteases, focusing on the role of residue 190 (including alanine 190) in inhibitor optimization.", "results_summary": "The study highlighted that inhibitors without a basic group have progressed into clinical use for proteases with alanine 190, but those with serine 190 remain challenging. It also noted the clinical adoption of new oral anticoagulants (NOACs) like apixaban, rivaroxaban, and edoxaban.", "population_specificity": "Not specified (review of existing literature and clinical practice)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:41:59.412401+00:00"}
{"study_id": 104769, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether baseline levels of alanine transaminase (ALT) and gamma-glutamyltransferase (GGT) could predict incident diabetes in Asian Indian men with impaired glucose tolerance (IGT).", "results_summary": "The study found that baseline GGT, but not ALT, was significantly higher in individuals who developed diabetes. GGT levels decreased in those who reverted to normal glucose tolerance (NGT) but increased in those who progressed to diabetes, indicating GGT as an independent predictor of diabetes risk.", "population_specificity": "Asian Indian men aged 35-55 years with impaired glucose tolerance (IGT).", "effective_dosage": "Not specified", "study_duration": "2 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:03.759238+00:00"}
{"study_id": 104771, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the efficacy and feasibility of gefitinib in elderly chemotherapy-naive patients with NSCLC harboring sensitive EGFR mutations, not specifically focusing on Alanine.", "results_summary": "The study found that gefitinib had an overall response rate of 61.2% and disease control rate of 83.8% in elderly NSCLC patients with EGFR mutations, with common adverse events including liver dysfunction (elevated alanine aminotransferase levels).", "population_specificity": "Elderly (\u226575 years) chemotherapy-naive patients with NSCLC and EGFR mutations (exon 19 deletion or exon 21 L858R mutation).", "effective_dosage": "250 mg/day of gefitinib.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:03.970379+00:00"}
{"study_id": 104772, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the preventive effects of Silybum marianum (not Alanine) against drug-induced liver injury among tuberculosis patients.", "results_summary": "The study found no significant preventive effect of silymarin in lowering the risk of liver injury or improving positive outcomes, and even suggested a potential risk of liver damage from the hepatoprotectant.", "population_specificity": "Tuberculosis patients in Jiangsu, China.", "effective_dosage": "Not specified for Alanine (study focused on S. marianum capsules and vitamin C tablets).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:04.076790+00:00"}
{"study_id": 104770, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers compared liver function, tumor characteristics, and survival outcomes between patients with cryptogenic HCC and alcohol-related HCC, focusing on AST/ALT ratios and other markers.", "results_summary": "The study found that alcohol-related HCC had worse liver function (higher AST/ALT ratio, MELD, and Child's scores), more aggressive tumor morphology, and lower median survival compared to cryptogenic HCC. No direct effects of alanine were assessed.", "population_specificity": "150 consecutive patients with HCC (89 cryptogenic HCC, 61 alcohol-related HCC).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:04.209013+00:00"}
{"study_id": 104774, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of resveratrol supplementation on cardiovascular risk factors, including alanine aminotransferase (ALT) levels, in patients with NAFLD.", "results_summary": "Resveratrol supplementation significantly reduced ALT and hepatic steatosis compared to placebo, but had no significant effect on anthropometric measurements, insulin resistance markers, lipid profile, or blood pressure.", "population_specificity": "Fifty patients with non-alcoholic fatty liver disease (NAFLD).", "effective_dosage": "500 mg resveratrol capsule daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:05.344930+00:00"}
{"study_id": 104773, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study evaluated the efficacy and safety of a combination regimen of gefitinib and pemetrexed in EGFR-mutated NSCLC patients, not specifically Alanine.", "results_summary": "The study found increased alanine aminotransferase levels as a grade 3 non-hematological toxicity in 11.5% of patients, but did not assess Alanine's effects.", "population_specificity": "Patients with advanced non-squamous NSCLC harboring a sensitive EGFR mutation.", "effective_dosage": "Not applicable (study did not focus on Alanine supplementation).", "study_duration": "Median of 16 treatment cycles (each cycle lasting 3 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:05.798077+00:00"}
{"study_id": 104775, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the relationship between liver function test alterations (including alanine aminotransferase [ALT]) and lipid administration patterns, particularly fish oil emulsions, in hospitalized adult patients receiving parenteral nutrition.", "results_summary": "The study found that ALT levels did not significantly increase during PN treatment, unlike other liver function markers (GGT and AP). Fish oil administration was associated with significant decreases in GGT and AP levels, while vegetal oil showed a tendency to increase these markers.", "population_specificity": "Hospitalized adult patients receiving parenteral nutrition over 4 years (n=1555).", "effective_dosage": "Not specified for alanine; fish oil dosage was measured in g\u00b7kg(-1)\u00b7d(-1).", "study_duration": "4 years (study period).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:06.908276+00:00"}
{"study_id": 104776, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy of autologous bone marrow mononuclear cell transplantation in decompensated liver disease, including its effects on alanine transaminase levels.", "results_summary": "The study found a temporary significant decrease in alanine transaminase levels in the cell transplantation group, though changes in other liver disease markers were not statistically significant.", "population_specificity": "Patients with decompensated liver disease.", "effective_dosage": "Not specified", "study_duration": "Follow-up periods included 1, 3, 6 months, and 1 year.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:08.129057+00:00"}
{"study_id": 104778, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to assess the effects of fish oil on metabolic abnormalities, including alanine aminotransferase levels, in patients with nonalcoholic fatty liver disease (NAFLD) associated with hyperlipidemia.", "results_summary": "Fish oil significantly reduced alanine aminotransferase levels (by a median of 9.0 IU/L) and improved other metabolic markers, suggesting benefits for NAFLD treatment. No adverse effects related to alanine were reported.", "population_specificity": "Eighty participants with NAFLD associated with hyperlipidemia.", "effective_dosage": "4 g/d of fish oil.", "study_duration": "3 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:15.027062+00:00"}
{"study_id": 104779, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the clinical features and factors associated with bilirubin increases during simeprevir with Peg-IFN plus ribavirin therapy in chronic hepatitis C patients.", "results_summary": "The study found that hyperbilirubinemia developed early in most cases and was dependent on the ITPA genotype, with bilirubin levels peaking within 6 weeks and gradually decreasing thereafter. The ITPA genotype (CC) was identified as the only independent factor associated with bilirubin increases.", "population_specificity": "192 patients with chronic hepatitis C", "effective_dosage": "Not specified", "study_duration": "Initial 12 weeks of simeprevir administration", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:15.084079+00:00"}
{"study_id": 104782, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether pioglitazone could reduce hepatic fat content and improve glycemic control in individuals with HIV/HCV coinfection and hepatic steatosis, with a secondary focus on trends in alanine aminotransferase (ALT) levels.", "results_summary": "Pioglitazone significantly reduced hepatic fat content and improved glycemic control, with trends toward improved ALT levels and histopathologic steatosis grade, though these were not statistically significant. The placebo group showed no significant changes.", "population_specificity": "13 subjects with HIV/HCV coinfection and hepatic steatosis.", "effective_dosage": "45 mg/day of pioglitazone.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:15.427503+00:00"}
{"study_id": 104777, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether lowering plasma triglyceride levels with fenofibrate or niacin affects plasma 1-deoxy-sphingolipid (1-deoxySL) levels, which are formed from L-alanine and glycine metabolism by serine-palmitoyltransferase (SPT).", "results_summary": "Fenofibrate significantly lowered 1-deoxySLs and other atypical sphingoid bases but had no effect on typical sphingolipids, while extended-release niacin did not affect 1-deoxySL levels despite lowering triglycerides.", "population_specificity": "Sixty-six patients with dyslipidemia.", "effective_dosage": "Fenofibrate (160 mg/d) or extended-release niacin (0.5 g/d for 3 wk, then 1 g/d).", "study_duration": "6 weeks per treatment with a 4-week washout between treatments.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:16.629142+00:00"}
{"study_id": 104780, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 95, "study_goal": "The researchers aimed to assess the safety and efficacy of entecavir versus placebo in nucleos(t)ide-na\u00efve children with HBeAg-positive chronic hepatitis B (CHB).", "results_summary": "Entecavir demonstrated significantly higher rates of HBeAg seroconversion, HBV DNA suppression, and alanine aminotransferase normalization compared to placebo, with a favorable safety profile and low resistance rates. Efficacy endpoints improved further between weeks 48 and 96.", "population_specificity": "Nucleos(t)ide-na\u00efve children (2 to <18 years) with HBeAg-positive chronic hepatitis B.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Minimum of 48 weeks (blinded treatment), with some patients continuing beyond 96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:16.867823+00:00"}
{"study_id": 104783, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the treatment rate and factors influencing the initiation of interferon-based antiviral treatment for chronic hepatitis C patients, including the role of alanine transaminase (ALT) levels.", "results_summary": "The study found that elevated ALT levels (>40 IU/L) were an independent factor associated with higher treatment initiation rates. However, the abstract does not specifically discuss the effects of alanine supplementation or its direct outcomes.", "population_specificity": "759 treatment-na\u00efve patients with chronic HCV infection, including chronic hepatitis C, liver cirrhosis, and hepatocellular carcinoma, from a multicenter Korean cohort.", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 769 days (interquartile range: 76-1,427 days)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:17.100159+00:00"}
{"study_id": 104781, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to examine the biochemical, obstetric management, and pregnancy outcomes in women with intrahepatic cholestasis of pregnancy (ICP) treated with ursodeoxycholic acid (UDCA), focusing on alanine aminotransferase (ALT) levels as a diagnostic marker.", "results_summary": "UDCA was well tolerated, but ALT levels were higher in the UDCA group at diagnosis. Preterm labor was more common in severe ICP cases (total BA >40 \u03bcmol/l), and ALT levels were significantly higher in these pregnancies. Apgar scores were lower in preterm babies, but umbilical artery pH values were unaffected.", "population_specificity": "Pregnant women with intrahepatic cholestasis of pregnancy (ICP) (N=307, with 208 receiving UDCA).", "effective_dosage": "Not specified (low-dose UDCA mentioned).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:17.101345+00:00"}
{"study_id": 104784, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effectiveness of pyridoxine (PN), pyridoxamine (PM), and pyridoxal (PL) in rescuing the effects of F152I and G170R mutations in alanine:glyoxylate aminotransferase (AGT) for treating primary hyperoxaluria type I (PH1).", "results_summary": "The study found that PM and PL were more effective than PN in rescuing AGT mutations, as they increased active coenzyme forms (PLP and PMP) without accumulating inactive PNP, which competes with PLP. This suggests PM and PL may be better therapeutic options for PH1 patients with folding mutations.", "population_specificity": "Patients with primary hyperoxaluria type I (PH1), particularly those with F152I and G170R mutations in AGT.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:18.278488+00:00"}
{"study_id": 104786, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to compare liver laboratory test requesting patterns by GPs in Spain to investigate the appropriateness of test usage.", "results_summary": "The study found high variability in liver test requests, with significant differences between communities and management types, and identified potential cost savings if target ratios were achieved.", "population_specificity": "GPs and clinical laboratories across diverse regions in Spain.", "effective_dosage": "Not available", "study_duration": "Data collected for the year 2012.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:22.940852+00:00"}
{"study_id": 104787, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to compare disease progression and outcomes between asymptomatic and symptomatic patients with autoimmune hepatitis (AIH), including differences in alanine aminotransferase levels.", "results_summary": "Asymptomatic AIH patients had significantly lower alanine aminotransferase and bilirubin levels at diagnosis compared to symptomatic patients, but similar disease progression and treatment responses.", "population_specificity": "305 patients (90 asymptomatic, 215 symptomatic) diagnosed with AIH between 1994 and 2013 at a specialized center in Italy.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:23.167919+00:00"}
{"study_id": 104785, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether l-alanine-derived 1-deoxysphingolipids play a role in paclitaxel-induced peripheral neuropathy.", "results_summary": "The study found that paclitaxel treatment elevated 1-deoxysphingolipid levels, particularly very-long-chain 1-deoxyceramides like C24, and these levels correlated with neuropathy severity, especially motor neuropathy.", "population_specificity": "27 patients with breast cancer treated with paclitaxel chemotherapy.", "effective_dosage": "Not specified for l-alanine; paclitaxel doses were 250 nM and 1 \u00b5M.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:23.476572+00:00"}
{"study_id": 104788, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers examined the role of alanine transaminase as a marker for cirrhosis diagnosis and its limitations in definitive identification.", "results_summary": "Abnormal alanine transaminase levels may suggest cirrhosis in chronic liver disease patients, but they are not definitive for diagnosis. Liver biopsy remains the gold standard, though noninvasive alternatives like elastography are being developed.", "population_specificity": "Patients at risk for cirrhosis or with chronic liver disease.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:23.842818+00:00"}
{"study_id": 104790, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were not attempting to determine anything about Alanine; the study focused on comparing TACE plus RT versus TACE alone for unresectable HCC.", "results_summary": "The study did not investigate Alanine's effects; it reported elevated levels of alanine transaminase as an adverse event in patients receiving TACE plus RT.", "population_specificity": "Patients with unresectable hepatocellular carcinoma (HCC).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:24.392259+00:00"}
{"study_id": 104789, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to update the management algorithm for chronic hepatitis B (CHB), including the role of antiviral therapies and monitoring alanine aminotransferase levels.", "results_summary": "The study found that elevated alanine aminotransferase levels, along with HBV DNA >2000 IU/mL and fibrosis, indicate the need for antiviral therapy in CHB patients. Preferred treatments include peginterferon alfa-2a, entecavir, and tenofovir.", "population_specificity": "Chronic hepatitis B (CHB) patients with elevated alanine aminotransferase levels and varying degrees of fibrosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:25.416623+00:00"}
{"study_id": 104791, "supplement_id": 863, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to investigate the safety and tolerability of a modified dAb (GSK2862277) with reduced binding to pre-existing HAVH autoantibodies, achieved by adding a single alanine residue at the C-terminus.", "results_summary": "The modified dAb (GSK2862277) showed reduced binding to pre-existing HAVH autoantibodies (from 51% to 7%) and was well tolerated in Phase I trials, though one subject experienced a mild infusion reaction due to a novel pre-existing antibody response. The study highlights challenges in developing biological antagonists for this receptor class.", "population_specificity": "Healthy subjects and donors in clinical trials.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:27.513117+00:00"}
{"study_id": 104792, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the impact of tenofovir disoproxil fumarate (TDF) on the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection, particularly among those without cirrhosis.", "results_summary": "Long-term TDF therapy was associated with a reduced incidence of HCC, especially in patients without cirrhosis, as the observed incidence was significantly lower than predicted by the REACH-B model. The overall HCC incidence was 0.37% per year, with lower rates in non-cirrhotic patients (0.28%) compared to cirrhotic patients (0.65%).", "population_specificity": "Patients with chronic HBV infection, including 634 individuals (152 with cirrhosis, 482 without).", "effective_dosage": "Not specified in the abstract.", "study_duration": "384 weeks (approximately 7.4 years).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:28.469246+00:00"}
{"study_id": 104796, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not investigate Alanine; it focuses on the effect of rosuvastatin monotherapy on non-alcoholic steatohepatitis (NASH).", "results_summary": "The study does not report any findings related to Alanine.", "population_specificity": "Patients with biopsy-proven NASH, metabolic syndrome, and dyslipidemia (n=20).", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:30.122123+00:00"}
{"study_id": 104797, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study did not evaluate Alanine; it focused on the safety and efficacy of enoxaparin sodium for thromboprophylaxis after cesarean section.", "results_summary": "The study did not investigate Alanine; it reported adverse events related to enoxaparin, including elevated alanine aminotransferase levels in some patients.", "population_specificity": "High-risk postpartum women after cesarean section in Japan.", "effective_dosage": "Not applicable (study did not involve Alanine).", "study_duration": "Not applicable (study did not involve Alanine).", "interactions": "None mentioned (study did not involve Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:31.849330+00:00"}
{"study_id": 104795, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and tolerability of fingolimod in relapsing-remitting MS patients from Latin America, including monitoring alanine aminotransferase enzyme levels.", "results_summary": "The study found that increases in alanine aminotransferase enzymes occurred in a small percentage of patients (3.7% \u22653x upper limit, 2.2% \u22655x, 0.7% \u226510x). Adverse events were mostly mild or moderate, with few discontinuations due to AEs.", "population_specificity": "162 patients with relapsing-remitting MS, predominantly from Latin American countries.", "effective_dosage": "Fingolimod 0.5 mg (frequency not specified).", "study_duration": "16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:32.313036+00:00"}
{"study_id": 104793, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess whether long-term entecavir monotherapy induces mitochondrial toxicity in patients with chronic hepatitis B (CHB), with a focus on mitochondrial DNA (mtDNA) content and depletion.", "results_summary": "The study found that mtDNA contents initially decreased and then increased over 4 years of entecavir monotherapy, while mtDNA4977 depletion rates first increased and then decreased. mtDNA content was negatively correlated with mtDNA4977 depletion and positively correlated with age.", "population_specificity": "34 antiviral treatment-na\u00efve patients with chronic hepatitis B (CHB).", "effective_dosage": "Not specified (entecavir monotherapy).", "study_duration": "4 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:32.693307+00:00"}
{"study_id": 104799, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not evaluate Alanine; it focuses on the efficacy and safety of B-mode ultrasound-guided PTGD combined with LC for acute cholecystitis in elderly and high-risk patients.", "results_summary": "The study does not report any findings related to Alanine.", "population_specificity": "Elderly and high-risk patients with acute cholecystitis.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.058584+00:00"}
{"study_id": 104798, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers compared the virologic response of entecavir monotherapy versus de novo lamivudine plus adefovir (LAM + ADV) combination therapy in HBeAg-positive chronic hepatitis B patients with high viral load.", "results_summary": "The study found no significant difference in virologic response between the two treatment groups at week 48, though baseline ALT levels \u22655 ULN or HBV DNA <8 log10 IU/ml predicted better response. Genotypic resistance was only observed in the LAM + ADV group.", "population_specificity": "HBeAg-positive chronic hepatitis B patients with high viral load (HBV DNA >1 \u00d7 10^7 copies/ml).", "effective_dosage": "Not specified", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:34.215398+00:00"}
{"study_id": 104800, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify clinical and biochemical parameters, including Alanine aminotransferase levels, that could predict the development of pancreatic pseudocysts after acute pancreatitis.", "results_summary": "The study found that Alanine aminotransferase levels at 48 hours were predictive of pancreatic pseudocyst formation in univariate analysis, but not in multivariate analysis, where low calcium levels at admission were the sole significant predictor.", "population_specificity": "102 patients diagnosed with acute pancreatitis.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:35.840717+00:00"}
{"study_id": 104801, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to assess the impact of HIV co-infection on hepatitis C progression, including alanine aminotransferase levels, in children.", "results_summary": "The study found that HCV/HIV co-infected children had higher alanine aminotransferase levels compared to HCV-monoinfected children, suggesting more severe liver involvement. No specific conclusions about alanine's therapeutic effects or safety were drawn.", "population_specificity": "HCV/HIV co-infected children and HCV-monoinfected children.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:38.262171+00:00"}
{"study_id": 104802, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of amino acids, including alanine, in protein-RNA and protein-glycan recognition codes and their potential applications in diagnostics and therapeutics.", "results_summary": "The study proposed that alanine, along with three other amino acids (glycine, valine, aspartic acid), may be part of an original genetic code influencing protein-RNA and protein-glycan interactions, with potential implications for disease diagnostics and therapy development.", "population_specificity": "Not specified (theoretical/research focus)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:39.965047+00:00"}
{"study_id": 104794, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 64, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of bezafibrate in improving liver function test (LFT) data, including alanine aminotransferase levels, in patients with primary sclerosing cholangitis (PSC).", "results_summary": "Bezafibrate improved biliary enzyme levels in all patients and hepatic enzyme levels in 64% of patients after 12 weeks. LFT data (including alanine aminotransferase) significantly decreased during treatment but increased after cessation.", "population_specificity": "Patients with primary sclerosing cholangitis (PSC).", "effective_dosage": "200 mg twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:39.974129+00:00"}
{"study_id": 104804, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to understand the role of specific residues, including alanine, in melittin's antimicrobial and lytic activity by studying analogues with proline substitutions.", "results_summary": "Studies revealed that proline-substituted melittin analogues, including those with alanine, showed decreased cytotoxicity and antimicrobial activity, with some mutants exhibiting enhanced pore formation compared to native melittin.", "population_specificity": "Model membrane systems and living cells (not human subjects).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:41.407511+00:00"}
{"study_id": 104803, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of WNK-STE20/SPS1-related proline/alanine-rich kinase (SPAK) in KCC-mediated cell volume regulation and its implications for neurological diseases.", "results_summary": "The study highlighted the evolutionary necessity of KCCs and SPAK for nervous system cell volume regulation, structure, and function, and their involvement in neurological disease. It also identified a swelling-activated dephosphorylation mechanism as a potential druggable switch for KCC activity.", "population_specificity": "Nervous system cells and genetic models (e.g., KCC3).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:41.797533+00:00"}
{"study_id": 104805, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to outline the mechanistic regulation of SGLT1/SGLT2, including the role of pathways involving alanine-rich kinase (Wnk/SPAK).", "results_summary": "The study highlights the regulation of SGLT expression via various pathways, including Wnk/SPAK, but does not specifically report on alanine's effects.", "population_specificity": "Not specified (focus on cellular and molecular mechanisms).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:41.813885+00:00"}
{"study_id": 104806, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the limitations of alanine aminotransferase monitoring in preventing drug-induced liver injury (DILI) and explore potential predictive biomarkers.", "results_summary": "The study highlights that alanine aminotransferase monitoring is often recommended but rarely effective in preventing serious DILI. It suggests that markers like microRNA-122 and keratin-18 may be more useful for identifying high-risk patients.", "population_specificity": "Patients at risk for drug-induced liver injury, including those with suspected acetaminophen overdose.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:42.536173+00:00"}
{"study_id": 104807, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to evaluate liver toxicity patterns, including alanine aminotransferase levels, in metastatic colorectal cancer patients treated with FOLFIRI-based chemotherapy.", "results_summary": "The study found significantly increased alanine aminotransferase levels during the first 3 months of treatment, indicating liver toxicity, with an R ratio suggesting mixed pattern injury.", "population_specificity": "156 metastatic colorectal cancer patients (91 male, 55 female; median age 62 years) treated at the University Campus Bio-Medico.", "effective_dosage": "Not specified (FOLFIRI-based chemotherapy regimen).", "study_duration": "First 3 months of treatment (full study period not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:44.858401+00:00"}
{"study_id": 104808, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of incretin-based therapies (GLP-1 RA and DPP-4I) in reducing serum alanine transaminase (ALT) levels and improving disease status in patients with NAFLD and comorbid T2DM.", "results_summary": "The meta-analysis found a significant decrease in serum ALT levels (mean reduction 14.1 IU/L) and improvements in steatosis, inflammation, and fibrosis in patients treated with incretin-based therapies.", "population_specificity": "Adults with NAFLD and concomitant type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:46.289644+00:00"}
{"study_id": 104812, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to characterize the population pharmacokinetics of kahalalide F (KF), a novel marine anticancer drug, in advanced cancer patients.", "results_summary": "The study found that KF exhibits linear elimination from plasma, dose-proportional exposure, and time-independent pharmacokinetics, with no clinically relevant covariates identified as predictors of its pharmacokinetic variability.", "population_specificity": "Advanced cancer patients", "effective_dosage": "266-6650 \u00b5g/m\u00b2, administered weekly or every 3 weeks", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:49.233711+00:00"}
{"study_id": 104809, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of autologous CD34(+) cell infusion in improving liver function in patients with non-viral decompensated cirrhosis.", "results_summary": "The study found that autologous CD34(+) cell infusion significantly improved serum albumin levels at 4 weeks and serum creatinine levels at 3 months, but these improvements were not sustained. There was no significant difference in transplant-free survival or mortality benefit compared to the control group.", "population_specificity": "Patients with non-viral decompensated cirrhosis (cryptogenic or alcohol-related).", "effective_dosage": "Granulocyte colony-stimulating factor injections 520 \u03bcg/d for 3 consecutive days, followed by CD34(+) cell infusion.", "study_duration": "Follow-up at 4 weeks and 3 months post-intervention.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:49.238719+00:00"}
{"study_id": 104813, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to assess the safety and efficacy of ultraviolet blood irradiation (UVBI) for treating hepatitis C virus (HCV) infection, not specifically Alanine.", "results_summary": "The study found a mean reduction in HCV viral load (21.5%) and improvements in liver function markers, including a 19.3% decline in alanine aminotransferase. Three patients showed significant viral load reductions, and two had improved psoriasis.", "population_specificity": "Nine patients with HCV infection.", "effective_dosage": "Not specified (UVBI treatments administered 15 times).", "study_duration": "22 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:49.888817+00:00"}
{"study_id": 104811, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to study the role of chronic hepatitis E in orthotopic liver transplant recipients, including the impact on alanine transaminase levels and treatment outcomes with ribavirin.", "results_summary": "The study found that HEV-infected patients had significantly higher alanine transaminase levels compared to non-infected patients. Ribavirin treatment normalized transaminase levels and cleared the infection in all patients, though one patient experienced a viral relapse.", "population_specificity": "287 adult orthotopic liver transplant recipients (59% male, median age 56 years).", "effective_dosage": "Ribavirin 400-800 mg/day, adjusted to renal function.", "study_duration": "3 months of ribavirin treatment (with one patient requiring re-treatment for 8 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:50.890274+00:00"}
{"study_id": 104814, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers compared intermittent Pringle with continuous hemihepatic vascular inflow occlusion techniques in laparoscopic liver resection, focusing on operative outcomes and postoperative recovery, including alanine aminotransferase levels.", "results_summary": "The study found that continuous hemihepatic vascular inflow occlusion resulted in shorter operative time, less blood loss, and better postoperative recovery, including lower alanine aminotransferase levels, compared to the Pringle method.", "population_specificity": "79 patients with liver tumors located in the right or left hemiliver undergoing laparoscopic liver resection.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:51.485864+00:00"}
{"study_id": 104816, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers were examining a case of disseminated varicella-zoster virus infection in a pediatric liver transplant patient, not evaluating the safety or efficacy of Alanine.", "results_summary": "The study reported a severe case of VZV infection post-liver transplantation, treated with acyclovir and immunosuppressant withdrawal, leading to eventual recovery. Alanine aminotransferase levels were noted as part of the diagnostic markers but were not the focus of the study.", "population_specificity": "12-year-old female with biliary atresia post-living donor liver transplantation.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:54.453340+00:00"}
{"study_id": 104815, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to identify risk factors for acute liver damage (ALD) associated with high-dose intravenous glucocorticoid (ivGC) pulse therapy in patients with Graves' orbitopathy (GO), focusing on alanine aminotransferase levels.", "results_summary": "The study found that age (\u226553 years) and higher methylprednisolone acetate (MPA) cumulative doses or doses per infusion significantly increased the risk of ALD. No ALD cases occurred with MPA doses per infusion below 0.57 g.", "population_specificity": "Patients with Graves' orbitopathy (GO) receiving ivGC therapy (n=1076).", "effective_dosage": "MPA cumulative dose (average 8.5 g in non-ALD patients), MPA dose per infusion (\u22650.7 g or <0.57 g).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:54.514451+00:00"}
{"study_id": 104819, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not address Alanine or its effects; it focuses on diagnostic controversies in pediatric NAFLD.", "results_summary": "The abstract does not discuss Alanine or its effects.", "population_specificity": "Pediatric patients with NAFLD.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:55.507337+00:00"}
{"study_id": 104810, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the efficacy of prolonged entecavir (ETV) therapy in treatment-naive chronic hepatitis B (CHB) patients and assess its feasibility for achieving HBeAg seroconversion, particularly in patients with partial virological response (PVR).", "results_summary": "Prolonged ETV therapy showed excellent virological response (98.2% at year 7), with low viral resistance (2.1%). HBeAg seroconversion was significantly higher in patients with virological response, but drug modification was needed for HBeAg-positive patients with PVR, especially those with high HBV DNA levels.", "population_specificity": "Treatment-naive chronic hepatitis B (CHB) patients (n=142), 60.6% HBeAg positive.", "effective_dosage": "Not specified", "study_duration": "Mean 65 months (range 26-90 months)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:55.680682+00:00"}
{"study_id": 104818, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the genetic basis, clinicopathologic features, and diagnostic and preventive strategies for Lynch syndrome in China, including the role of alanine aminopeptidase among other MMR-associated genes.", "results_summary": "The abstract mentions alanine aminopeptidase as one of the MMR-associated genes implicated in Chinese Lynch syndrome, but no specific effects or outcomes related to alanine are detailed.", "population_specificity": "Chinese individuals with Lynch syndrome.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:56.826675+00:00"}
{"study_id": 104817, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether poly-unsaturated fatty acid (PUFA) therapy, which includes alanine aminotransferase (ALT) as a marker, could improve nonalcoholic steatohepatitis (NASH).", "results_summary": "PUFA therapy significantly reduced ALT and AST levels, improved lipid profiles, inflammation, oxidation markers, and histological parameters in NASH patients compared to controls.", "population_specificity": "78 patients pathologically diagnosed with NASH.", "effective_dosage": "50 mL PUFA (1:1 ratio of EHA and DHA) added to daily diet.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:57.916744+00:00"}
{"study_id": 104820, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 68, "study_goal": "The researchers aimed to assess the biochemical and oxidative status of dengue fever patients, including alterations in serum alanine aminotransferase (ALT) levels.", "results_summary": "The study found significant increases in serum ALT levels (P=0.000) in dengue fever patients, indicating liver involvement. A positive correlation was observed between liver enzymes and circulating antioxidants.", "population_specificity": "101 confirmed dengue fever patients referred to the pathology lab of Jinnah Hospital Lahore.", "effective_dosage": "Not specified", "study_duration": "Data collected from August 2010 to December 2011 (study duration, not intervention)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:42:59.448864+00:00"}
{"study_id": 104821, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 48, "quality_score": 75, "study_goal": "The researchers aimed to compare the effectiveness and clinical impact of a half-dose L-T4 protocol versus conventional L-T4 withdrawal in thyroid cancer patients, including effects on biochemical markers like alanine aminotransferase.", "results_summary": "The study found that alanine aminotransferase levels increased in both groups but significantly more in the conventional withdrawal group. The half-dose protocol resulted in fewer biochemical disorders but only achieved the target TSH level in 48.3% of patients, requiring a basal TSH \u22650.52 \u03bcU/ml for effectiveness.", "population_specificity": "55 thyroid cancer patients post-thyroidectomy.", "effective_dosage": "Half-dose of previous L-T4 treatment (specific amount not stated).", "study_duration": "5 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:00.355537+00:00"}
{"study_id": 104822, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the use of tenofovir in HBV-HIV-coinfected patients and its effects on alanine transaminase levels and CD4(+) T-cell response.", "results_summary": "Tenofovir-based regimens more effectively reduced liver inflammation (measured by alanine transaminase levels) in HBV-HIV-coinfected patients compared to non-tenofovir regimens, but did not significantly improve CD4(+) T-cell recovery.", "population_specificity": "HBV-HIV-coinfected patients in Asia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:01.850017+00:00"}
{"study_id": 104824, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to quantify the treatment response of vitamin E in improving liver function and histology in patients with NAFLD/NASH.", "results_summary": "Vitamin E significantly reduced AST, ALT, ALP, steatosis, inflammation, and hepatocellular ballooning in NAFLD/NASH patients. It also showed reductions in fibrosis in NASH adult patients.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:03.320395+00:00"}
{"study_id": 104823, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to identify practical predictive parameters for visceral obesity, including the role of serum alanine aminotransferase levels, in nondiabetic obese adults.", "results_summary": "Increased serum alanine aminotransferase levels were correlated with larger visceral fat area (VFA), but after adjustment for other factors, only serum triglyceride level remained an independent correlate of VFA. Alanine aminotransferase was not a significant predictor in the final multivariate models.", "population_specificity": "51 nondiabetic obese adults (BMI \u2265 27 kg/m\u00b2) in Taiwan (21 men, 30 women, mean age 35.6 \u00b1 9.2 years).", "effective_dosage": "Not specified", "study_duration": "Not specified (cross-sectional study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:03.613499+00:00"}
{"study_id": 104825, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to compare the effectiveness and safety of combination therapy (UDCA and fenofibrate) versus UDCA monotherapy in treating primary biliary cirrhosis (PBC), with a focus on biochemical markers including alanine aminotransferase (ALT).", "results_summary": "The study found no significant difference in ALT levels between combination therapy and monotherapy (MD: -3.31 IU/L; P=0.56). Combination therapy improved other liver markers but did not significantly affect clinical symptoms or ALT.", "population_specificity": "Patients with primary biliary cirrhosis (84 participants across six trials).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:04.217112+00:00"}
{"study_id": 104826, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to investigate the efficacy of rifaximin on NAFLD, particularly its impact on liver enzymes like alanine aminotransferase (ALT) and inflammatory markers.", "results_summary": "Rifaximin significantly reduced ALT levels in both NASH and steatosis groups, along with improvements in other liver enzymes and inflammatory markers like endotoxin and IL-10, though no significant effect was observed on TLR-4, IL-1, IL-6, IL-12, or TNF-\u03b1.", "population_specificity": "42 patients with biopsy-proven NAFLD (15 with steatosis, 27 with NASH).", "effective_dosage": "1200 mg daily.", "study_duration": "28 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:05.782509+00:00"}
{"study_id": 104827, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to assess the influence of different PEEP values on liver blood flow using ICG clearance tests, including alanine aminotransferase levels, in liver donor patients.", "results_summary": "The study found no significant differences in ICG clearance rates between PEEP groups, but noted changes in PT, INR, Hgb, and Hct values. Alanine aminotransferase levels were analyzed but no specific results regarding its efficacy or safety were highlighted.", "population_specificity": "40 patients undergoing right hepatectomy as liver donors.", "effective_dosage": "Not specified", "study_duration": "Measurements were taken at multiple time points from pre-anesthesia to 72 hours postoperatively.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:07.031919+00:00"}
{"study_id": 104828, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to investigate the relationship between gallstone disease and nonalcoholic fatty liver disease (NAFLD), not specifically Alanine.", "results_summary": "The study found that cholecystectomy, but not gallstones, was independently associated with NAFLD after adjusting for metabolic risk factors. Alanine aminotransferase levels were reviewed as part of laboratory parameters but were not the focus of the study.", "population_specificity": "17,612 subjects from general health check-ups at Seoul National University Hospital, Healthcare System Gangnam Center (mean age 48.5 \u00b1 11.3 years, 49.3% male).", "effective_dosage": "Not available", "study_duration": "Cross-sectional study conducted between January 2010 and December 2010.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:08.594729+00:00"}
{"study_id": 104829, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of dihydromyricetin (a compound related to Alanine metabolism) on glucose and lipid metabolism, inflammatory mediators, and biomarkers in nonalcoholic fatty liver disease patients.", "results_summary": "Dihydromyricetin supplementation significantly reduced serum levels of alanine, aspartate aminotransferase, \u03b3-glutamyl transpeptidase, glucose, low-density lipoprotein-cholesterol, apolipoprotein B, and HOMA-IR index, while decreasing inflammatory markers and increasing adiponectin levels.", "population_specificity": "Sixty adult patients with nonalcoholic fatty liver disease.", "effective_dosage": "150 mg twice daily.", "study_duration": "Three months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:09.084731+00:00"}
{"study_id": 104830, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to elucidate the role of lactate formation, including alanine kinetics, in muscle energy production during exercise in patients with McArdle disease.", "results_summary": "McArdle patients showed a marked decrease in plasma lactate concentration during exercise, with substantial leg net lactate uptake and oxidation, while also exhibiting unidirectional lactate release similar to healthy controls. Alanine kinetics were measured but not highlighted as a primary outcome.", "population_specificity": "Four patients with McArdle disease and seven healthy subjects.", "effective_dosage": "Not specified", "study_duration": "40 minutes of exercise", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:10.317588+00:00"}
{"study_id": 104831, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate whether DHA supplementation improves hepatic fat, cardiovascular disease risk factors, and metabolic abnormalities in children with NAFLD.", "results_summary": "DHA supplementation significantly reduced liver fat, visceral adipose tissue, and epicardial adipose tissue compared to placebo, and improved fasting insulin and triglyceride levels, but did not significantly affect LV function, BMI-SDS, or ALT.", "population_specificity": "Children with biopsy-proven nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified in the abstract.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:11.691881+00:00"}
{"study_id": 104832, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the current status of known inhibitors of alanine racemase enzyme, focusing on their potential as antibacterial drug targets.", "results_summary": "The abstract highlights that alanine racemase is a promising antibacterial target due to its absence in humans, but existing inhibitors like d-cycloserine have severe toxic effects, prompting the search for non-substrate analog inhibitors. The review provides updated structural information on known inhibitors to aid in developing selective and potent alternatives.", "population_specificity": "Not specified (focus on bacterial enzyme inhibition).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:12.663618+00:00"}
{"study_id": 104833, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the accuracy and feasibility of a paper-based microfluidic assay for measuring alanine aminotransferase (ALT) in fingerstick and serum samples compared to established reference methods.", "results_summary": "The paper test showed excellent agreement with the Abaxis reference method for serum testing, with negligible bias (+4.5 U/L). A systematic difference was found between fingerstick and serum ALT values, but a correction factor was developed to address this. Remote reading via cell phone images was feasible and closely matched real-time readings.", "population_specificity": "96 ambulatory patients with varied baseline ALT concentrations.", "effective_dosage": "Not applicable (diagnostic test evaluation).", "study_duration": "Not applicable (single testing event).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:13.102235+00:00"}
{"study_id": 104834, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the treatment outcomes of entecavir (ETV) and tenofovir (TDF) in routine clinical practice for chronic hepatitis B, focusing on viral suppression rates and medication adherence.", "results_summary": "Both ETV and TDF showed similar rates of complete viral suppression (87.7% vs. 87.0% at 24 months), with suboptimal responses primarily linked to medication nonadherence. Virological breakthrough rates were higher in the TDF group, particularly at 24 months (9.8% vs. 3.7% for ETV).", "population_specificity": "Treatment-naive chronic hepatitis B patients (443 on ETV, 114 on TDF), predominantly Asian, HBeAg-negative males with similar baseline alanine aminotransferase and HBV DNA levels.", "effective_dosage": "Not specified", "study_duration": "24 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:15.552342+00:00"}
{"study_id": 104836, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the role of HIF-1\u03b1 in liver ischemia-reperfusion injury (IRI) and its potential protective effects, including the impact on alanine aminotransferase (ALT) levels.", "results_summary": "Stabilized HIF-1\u03b1 treatment was associated with lower ALT levels (SMD = -1.58) compared to unstabilized HIF-1\u03b1, indicating reduced liver injury and improved graft regeneration capacity. The study also highlighted the protective effect of ischemic preconditioning (IPC) linked to higher HIF-1\u03b1 levels.", "population_specificity": "Clinical trials (n=68) and animal studies (n=66) focused on liver transplantation and ischemia-reperfusion injury.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:17.722064+00:00"}
{"study_id": 104837, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to develop predictive models for HBeAg seroconversion in chronic hepatitis B patients treated with IFN-\u03b1, using serum alanine aminotransferase (ALT) and other biomarkers.", "results_summary": "The study identified key biomarkers (ALT, HBeAg, anti-HBc) at baseline, 12 weeks, and 24 weeks that strongly correlated with HBeAg seroconversion, with response rates up to 84% when all predictive factors were present.", "population_specificity": "147 treatment-na\u00efve HBeAg-positive chronic hepatitis B patients in China.", "effective_dosage": "Not specified (IFN-\u03b11b treatment details not provided).", "study_duration": "52 weeks (with assessments at 12, 24, and 52 weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:18.196927+00:00"}
{"study_id": 104838, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 88, "study_goal": "The researchers aimed to compare the efficacy and safety of tenofovir disoproxil fumarate (TDF) in Asian and non-Asian chronic hepatitis B (CHB) patients, including its effects on alanine aminotransaminase (ALT) levels.", "results_summary": "The study found that TDF demonstrated similar viral suppression and normalization of ALT levels in both Asian and non-Asian patients, with no detectable resistance and no renal safety signals. Liver histology improved in a majority of patients, though HBeAg loss and seroconversion rates were higher in non-Asians.", "population_specificity": "Chronic hepatitis B (CHB) patients, both Asian (n=217) and non-Asian (n=299).", "effective_dosage": "Not specified in the abstract.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:19.576547+00:00"}
{"study_id": 104839, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the efficacy and safety of regorafenib in Asian patients with refractory metastatic colorectal cancer, not specifically Alanine.", "results_summary": "The study found that regorafenib significantly improved overall survival compared to placebo in Asian patients with refractory metastatic colorectal cancer, with common adverse events including hand-foot skin reaction and hypertension. Alanine aminotransferase concentration increases were noted as a side effect in some patients.", "population_specificity": "Asian patients aged 18+ with progressive metastatic colorectal cancer who had received at least two previous treatment lines or were unable to tolerate standard treatments.", "effective_dosage": "Oral regorafenib 160 mg once daily on days 1-21 of each 28-day cycle.", "study_duration": "Median follow-up of 7.4 months (IQR 4.3-12.2).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:21.130757+00:00"}
{"study_id": 104840, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of post-screening care strategies, including ALT monitoring and treatment referral, for anti-HCV-positive subjects in the community.", "results_summary": "The study found that active referral and accessible medical care programs increased treatment uptake among HCV-positive subjects, with varying rates of sustained virological response (SVR) achieved. Simple notification resulted in 9.2% treatment uptake, while active referral and accessible care programs increased this to 3.6% and 32.6%, respectively.", "population_specificity": "Anti-HCV-positive subjects, primarily those aged less than 65 years with elevated ALT levels (>80 IU/L), and elderly HCV residents in Yujing township.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:22.594627+00:00"}
{"study_id": 104841, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the prevalence and incidence of liver dysfunction, including ALT levels, in children with HIV before and after initiating combination antiretroviral therapy (cART).", "results_summary": "The study found a low prevalence (5.8%) of elevated ALT levels before cART and a low incidence (1.19 per 1000 person-months) of ALT elevation after cART initiation. Baseline hemoglobin <7.5 g/dL was a predictor of ALT elevation, while age 5-9 years at cART initiation was protective against liver dysfunction.", "population_specificity": "Children aged 2-18 years with perinatal HIV infection, predominantly on non-nucleoside reverse transcriptase-based cART regimens.", "effective_dosage": "Not specified", "study_duration": "Data analyzed between 2008 and 2012 (follow-up duration not explicitly stated)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:23.005624+00:00"}
{"study_id": 104835, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the efficacy and safety of oral oxymatrine preparation (containing alanine-related compounds) for treating chronic hepatitis B (CHB).", "results_summary": "Oral oxymatrine preparation showed statistically significant effects on clearing HBV DNA, HBV surface antigen, and HBV e antigen, and improved normalization of serum alanine aminotransferase and aspartate aminotransferase. However, the overall methodological quality and evidence were poor, and safety was unconfirmed.", "population_specificity": "Patients with chronic hepatitis B (5,227 participants across 52 RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:23.955981+00:00"}
{"study_id": 104842, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate whether serum galectin-3 (GAL-3) levels could serve as a marker for monitoring disease status in children with chronic HBV infection, with a focus on alanine aminotransferase (ALT) levels as part of the assessment.", "results_summary": "The study found significantly higher serum GAL-3 and ALT levels in children with chronic hepatitis B (CHB) compared to inactive carriers and healthy controls, suggesting GAL-3 may be a useful indicator of chronic HBV infection. A strong correlation was observed between GAL-3 and ALT levels in the CHB group.", "population_specificity": "Children with chronic HBV infection (32 CHB patients, 30 inactive carriers, and 30 healthy controls).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:25.400087+00:00"}
{"study_id": 104845, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the performance of the PAPAS index, which includes alanine transaminase (ALT), in predicting significant fibrosis and cirrhosis in chronic hepatitis C (CHC) patients compared to other noninvasive tests.", "results_summary": "The PAPAS index showed moderate efficiency in predicting significant fibrosis and cirrhosis, comparable to other fibrosis markers like FIB4 and GUCI, but was not superior. No statistically significant differences were observed among the tested predictors.", "population_specificity": "137 consecutive patients with chronic hepatitis C who underwent percutaneous liver biopsy before treatment.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:27.284372+00:00"}
{"study_id": 104844, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and maximum tolerated dose (MTD) of afatinib combined with nintedanib, not specifically Alanine.", "results_summary": "The study identified dose-limiting toxicities, including increased alanine aminotransferase, but did not focus on Alanine's effects. The MTD was determined to be afatinib 10 mg daily plus nintedanib 200 mg twice daily.", "population_specificity": "Patients receiving afatinib and nintedanib (specific condition not detailed).", "effective_dosage": "Afatinib 10-20 mg daily plus nintedanib 150-200 mg twice daily.", "study_duration": "28-day cycle (specific number of cycles not detailed).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:27.474372+00:00"}
{"study_id": 104843, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine whether antiviral therapy (AVT) should be recommended for compensated cirrhosis patients with chronic HBV infection and low HBV-DNA levels, focusing on HCC risk.", "results_summary": "The study found that patients with detectable but low HBV-DNA levels were not at low risk for HCC, and AVT was associated with lower HCC risk, suggesting prompt AVT consideration.", "population_specificity": "Treatment-na\u00efve, HBV-related compensated cirrhosis patients (mean age 51.1 \u00b1 9.7 years; 66% male) with low HBV-DNA levels (<2,000 IU/mL).", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 5.6 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:27.643521+00:00"}
{"study_id": 104846, "supplement_id": 863, "safety_score": "80", "efficacy_score": 90, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of an all-oral therapy regimen (including daclatasvir, asunaprevir, and beclabuvir) with or without ribavirin for treating chronic HCV genotype 1 infection in patients with cirrhosis.", "results_summary": "The study found high sustained virologic response rates (SVR12) of 93-98% in treatment-naive and 87-93% in treatment-experienced patients, with ribavirin enhancing efficacy. Adverse events were limited, with few serious treatment-related events and discontinuations.", "population_specificity": "Adult patients with chronic HCV genotype 1 infection and compensated cirrhosis, including treatment-naive and treatment-experienced individuals.", "effective_dosage": "Fixed-dose combination of daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) twice daily, with or without weight-based ribavirin (1000-1200 mg/d).", "study_duration": "12 weeks of treatment, with 24 weeks of follow-up.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:31.990094+00:00"}
{"study_id": 104848, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effect of Shenfu decoction (SFD) on quality of life and hepatic function, including plasma alanine aminotransferase (ALT) levels, in symptomatic chronic heart failure (CHF) patients.", "results_summary": "SFD significantly improved quality of life scores (MLHFQ), reduced ALT levels, enhanced cardiac function, increased LVEF, and lowered TNF-\u03b1 levels compared to standard therapy alone.", "population_specificity": "Forty symptomatic chronic heart failure patients (18 in SFD group, 22 in control group).", "effective_dosage": "Not specified (Shenfu granules administered for 14 days).", "study_duration": "14 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:32.360728+00:00"}
{"study_id": 104849, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate whether switching from oral iron to intravenous ferric carboxymaltose could reduce ESA requirements and improve iron status and hemoglobin in patients with non-dialysis-dependent chronic kidney disease (ND-CKD).", "results_summary": "The study found that switching to intravenous ferric carboxymaltose significantly reduced ESA consumption by 83.2%, increased hemoglobin by 0.7 g/dL, and improved iron parameters (ferritin and transferrin saturation) without reported adverse events.", "population_specificity": "Adult patients with ND-CKD (creatinine clearance \u226440 mL/min), hemoglobin 11-12 g/dL, and iron deficiency (ferritin <100 \u03bcg/L or transferrin saturation <20%).", "effective_dosage": "1,000 mg iron (initial dose), followed by a 6-month maintenance regimen.", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.287648+00:00"}
{"study_id": 104850, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize recent advances in understanding the role of autophagy in liver pathophysiology and its potential as a therapeutic target for liver disease.", "results_summary": "The abstract highlights that autophagy regulates hepatic apoptosis and plays a critical role in liver disease progression, suggesting it as a novel therapeutic target. However, no specific findings related to Alanine are mentioned.", "population_specificity": "Pre-clinical models and clinical trials (no specific human or animal population detailed).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:33.344753+00:00"}
{"study_id": 104851, "supplement_id": 863, "safety_score": "75", "efficacy_score": 60, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of perimenstrual telcagepant, a CGRP receptor antagonist, for headache prophylaxis, with a focus on its effects on alanine aminotransferase levels.", "results_summary": "Telcagepant was generally well tolerated but associated with transaminase elevations, including alanine aminotransferase elevations \u2265 3x normal in 0.6% of women. It did not significantly reduce monthly headache frequency but showed a reduction in perimenstrual headache days.", "population_specificity": "Women with migraine for \u2265 3 months who experienced perimenstrual headaches.", "effective_dosage": "140 mg taken for seven consecutive days perimenstrually.", "study_duration": "Six-month trial.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:35.704389+00:00"}
{"study_id": 104852, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the associations of HIV infection and CD4 count with markers of hepatocellular damage, including elevated alanine aminotransferase (ALT), in HIV-infected and uninfected Rwandan women.", "results_summary": "The study found that HIV-infected women, particularly those with CD4 counts <200 cells/\u03bcl, had a higher prevalence of abnormal ALT levels compared to uninfected women. The odds of low serum albumin, a marker of liver synthetic function, were significantly higher in HIV-infected women, decreasing with higher CD4 counts.", "population_specificity": "HIV-infected (ART-naive) and uninfected Rwandan women.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:35.705916+00:00"}
{"study_id": 104853, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the effects of entecavir (ETV) and lamivudine (LAM) on reducing hepatitis B virus (HBV) cccDNA and total hepatic HBV DNA, with a focus on alanine aminotransferase (ALT) as a biomarker.", "results_summary": "ETV showed significantly greater reductions in hepatic HBV cccDNA and total hepatic HBV DNA compared to LAM after 48 weeks. Changes in cccDNA levels were associated with baseline serum HBV DNA, ALT, and other on-treatment factors.", "population_specificity": "Nucleos(t)ide-naive, HBeAg-positive patients with chronic hepatitis B.", "effective_dosage": "ETV (0.5 mg daily) or LAM (100 mg daily).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:36.888404+00:00"}
{"study_id": 104854, "supplement_id": 863, "safety_score": "40", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the safety and efficacy of mipomersen, which affects alanine aminotransferase levels, in reducing LDL-C and other lipid parameters in adults with dyslipidemia.", "results_summary": "Mipomersen significantly reduced LDL-C, total cholesterol, and other lipid parameters but did not change HDL-C. It increased risks of injection-site reactions, flu-like symptoms, hepatic steatosis, and elevated alanine aminotransferase levels.", "population_specificity": "Adults with dyslipidemia (n=462).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:40.352049+00:00"}
{"study_id": 104857, "supplement_id": 863, "safety_score": "85", "efficacy_score": 70, "quality_score": 90, "study_goal": "The researchers aimed to determine whether 12 weeks of acetaminophen use at half the maximum recommended daily dose increases alanine transaminase (ALT) levels in healthy adults.", "results_summary": "The study found a small but statistically significant increase in mean ALT levels in the acetaminophen group compared to placebo, though the elevation was deemed of no probable clinical significance. No progressive increase in ALT was observed during the trial.", "population_specificity": "Healthy adults aged 18-65 with mild to moderate asthma and no history of liver dysfunction.", "effective_dosage": "1g of acetaminophen twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:41.143455+00:00"}
{"study_id": 104855, "supplement_id": 863, "safety_score": "70", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine the recommended phase II dose of LY2780301, a dual p70 S6 kinase and Akt inhibitor, and assess its safety, pharmacokinetics, and pharmacodynamics in patients with advanced cancer.", "results_summary": "The study found minimal antitumor activity and transient pharmacodynamic effects, with common toxicities including constipation, fatigue, nausea, and diarrhea. Plasma exposures exceeded predicted efficacious levels but were not dose-proportional, and S6 inhibition in skin biopsies was not maintained.", "population_specificity": "Patients with advanced cancer.", "effective_dosage": "100-500 mg daily, given orally as a single dose or divided into 2 doses.", "study_duration": "28-day cycles.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:41.393849+00:00"}
{"study_id": 104856, "supplement_id": 863, "safety_score": "65", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to characterize liver chemistry abnormalities, particularly alanine aminotransferase (ALT) elevations, associated with pazopanib treatment.", "results_summary": "The study found that 20% of pazopanib-treated patients developed elevated ALT >3\u00d7ULN, with varying severity and recovery rates. Older age was associated with higher ALT elevations, but no deaths were linked to drug-induced liver injury, and rechallenge with pazopanib was generally safe.", "population_specificity": "Pazopanib-treated patients from nine prospective trials (N=2080).", "effective_dosage": "Not specified", "study_duration": "Median time to onset of ALT elevation was 42 days; 91% of events occurred within 18 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:41.996523+00:00"}
{"study_id": 104847, "supplement_id": 863, "safety_score": "70", "efficacy_score": 91, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a ribavirin-free, all-oral regimen (including daclatasvir, asunaprevir, and beclabuvir) for treating chronic HCV genotype 1 infection, with a focus on sustained virologic response (SVR) rates.", "results_summary": "The study found high SVR12 rates (91.3% overall, 92.0% in treatment-naive, and 89.3% in treatment-experienced patients) with the regimen. Adverse events included headache, fatigue, diarrhea, nausea, and rare cases of grade 4 alanine aminotransferase elevations.", "population_specificity": "Noncirrhotic patients with chronic HCV genotype 1 infection, including treatment-naive (n=312) and treatment-experienced (n=103) individuals.", "effective_dosage": "Twice-daily fixed-dose combination of daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg).", "study_duration": "12 weeks of treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:43.514063+00:00"}
{"study_id": 104859, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to investigate the association between primary Epstein-Barr Virus (EBV) infection and acute acalculous cholecystitis (AAC), particularly in young women.", "results_summary": "The study found that primary EBV infection can lead to AAC, especially in young women, and cases typically recover without surgical intervention or antibiotics. Elevated liver enzymes, including alanine aminotransferase (61 U/l), were noted, indicating cholestasis.", "population_specificity": "34-year-old woman with primary EBV infection and AAC, with a literature review of 26 similar cases (25 females).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:43.956702+00:00"}
{"study_id": 104858, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers were examining whether HIV infection status predicted receipt of HCV RNA testing after a positive HCV antibody result, with elevated alanine aminotransferase levels as a secondary factor.", "results_summary": "The study found that HIV-positive patients were more likely to receive HCV RNA testing (77.4%) compared to HIV-negative patients (66.7%). Elevated alanine aminotransferase levels were also associated with higher odds of receiving HCV RNA testing.", "population_specificity": "Anti-HCV+ patients aged \u226518 years who utilized primary care outpatient services during 2005-2010.", "effective_dosage": "Not available", "study_duration": "Not applicable (retrospective study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:44.294834+00:00"}
{"study_id": 104860, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers were comparing the efficacy and safety of nilotinib versus imatinib as first-line therapy for advanced gastrointestinal stromal tumours (GISTs), not specifically studying alanine.", "results_summary": "The study found that nilotinib was less effective than imatinib in terms of progression-free survival for GIST patients. Elevated alanine aminotransferase concentration was noted as a common grade 3-4 adverse event in the nilotinib group.", "population_specificity": "Patients aged 18+ with previously untreated, metastatic or unresectable GISTs.", "effective_dosage": "Not applicable (study focused on nilotinib and imatinib, not alanine).", "study_duration": "Data cutoff was October 2012, with enrollment from March 2009 to April 2011.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:46.995032+00:00"}
{"study_id": 104863, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to review the roles of protocadherins (Pcdhs) and atypical cadherins in dendritogenesis, dendrite arborization, and dendritic spine regulation, and their potential as therapeutic targets for neurodevelopmental disorders.", "results_summary": "The abstract highlights that Pcdhs and atypical cadherins are key regulators of dendrite development and function, suggesting their potential as therapeutic targets for neurodevelopmental disorders. No specific findings about Alanine are mentioned.", "population_specificity": "Not specified (review of existing studies on neural circuit formation and neurodevelopmental disorders).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:48.870338+00:00"}
{"study_id": 104862, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effects of carnitine-orotate complex (which includes alanine) on serum ALT levels and hepatic steatosis in patients with diabetes and NAFLD.", "results_summary": "The study found that carnitine-orotate complex significantly increased the rate of ALT normalization (89.7% vs. 17.9%) and improved hepatic steatosis on CT imaging. It also showed a significant decrease in HbA1c levels in the treatment group.", "population_specificity": "Patients with nonalcoholic fatty liver disease (NAFLD) and diabetes from eight hospitals in Korea.", "effective_dosage": "824 mg, three times daily", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:49.223708+00:00"}
{"study_id": 104861, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the effect of adding pazopanib to paclitaxel for patients with platinum-resistant or platinum-refractory advanced ovarian cancer, not specifically Alanine.", "results_summary": "The study found that pazopanib plus paclitaxel significantly improved progression-free survival compared to paclitaxel alone, with no unexpected toxic effects, though adverse events were more common in the combination group. Alanine aminotransferase elevation was noted as an adverse event in the pazopanib group.", "population_specificity": "Patients with platinum-resistant or platinum-refractory ovarian cancer, previously treated with a maximum of two lines of chemotherapy, and with Eastern Cooperative Oncology Group performance status 0-1.", "effective_dosage": "Not specified for Alanine.", "study_duration": "Median follow-up was 16.1 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:49.921504+00:00"}
{"study_id": 104864, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to assess steroid responsiveness in IgG4-related sclerosing cholangitis (IgG4-SC) patients, including changes in serum alanine aminotransferase levels.", "results_summary": "Elevated serum alanine aminotransferase levels were halved in 25% of patients at 5 days and 38% at 10 days after starting steroid therapy. Steroid responsiveness was more evident in lower bile duct involvement than hilar/intrahepatic bile duct involvement.", "population_specificity": "29 patients with IgG4-SC (lower bile duct involvement, n=29; hilar/intrahepatic bile duct involvement, n=6).", "effective_dosage": "Not specified", "study_duration": "Assessments were made at 5, 10, and 15 days after commencing steroid therapy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:51.644628+00:00"}
{"study_id": 104865, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the severity of acute hepatitis E virus (HEV) infection and the risk of chronic viral replication in patients with inflammatory arthritides treated with immunosuppressive drugs.", "results_summary": "The study found that acute HEV infection in patients with inflammatory rheumatism and elevated liver enzyme levels had a favorable outcome, with no evolution to chronic hepatitis or fulminant liver failure. Liver enzyme levels normalized, and immunosuppressant therapy could be reinitiated in all patients.", "population_specificity": "Patients with inflammatory arthritides (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, other types) treated with immunosuppressive drugs.", "effective_dosage": "Not specified for Alanine", "study_duration": "Median follow-up was 29 months (range 3-55)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:52.766591+00:00"}
{"study_id": 104868, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-to-infant hepatitis B virus (HBV) transmissions and its effects on maternal alanine aminotransferase (ALT) levels.", "results_summary": "The study found that TDF treatment significantly reduced maternal HBV DNA levels, lowered infant HBV DNA positivity at birth, and decreased infant HBsAg positivity at 6 months. Additionally, TDF ameliorated maternal ALT elevations, with fewer instances of ALT levels exceeding normal limits.", "population_specificity": "Hepatitis B surface antigen (HBsAg)- and hepatitis B e antigen-positive pregnant women with HBV DNA \u22657.5 log10 IU/mL.", "effective_dosage": "300 mg daily", "study_duration": "From 30-32 weeks of gestation until 1 month postpartum", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:53.278850+00:00"}
{"study_id": 104869, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of Yinchenhao decoction, which includes alanine aminotransferase (ALT) as a biochemical marker, in treating cholestasis.", "results_summary": "Yinchenhao decoction significantly reduced elevated levels of ALT and other cholestasis serum markers, demonstrating efficacy in both short and long-term treatment periods with no serious adverse events reported.", "population_specificity": "1405 subjects with cholestasis.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:54.997003+00:00"}
{"study_id": 104867, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the incidence of antiviral-resistant HBV mutations in HIV-HBV-coinfected patients undergoing long-term antiretroviral therapy, comparing lamivudine (LAM) and tenofovir/emtricitabine (TDF/FTC) regimens.", "results_summary": "The study found that antiviral resistance, particularly to LAM, was rare in HIV-HBV-coinfected patients, with 74.2% achieving undetectable HBV DNA on LAM-containing ART and 94.2% on TDF/FTC-containing ART after ~35.5 months. No baseline resistance mutations were observed, and only two patients developed LAM-resistance mutations.", "population_specificity": "ART-naive HIV-HBV-coinfected patients from sub-Saharan Africa (C\u00f4te d'Ivoire).", "effective_dosage": "Not specified for alanine (study focused on LAM and TDF/FTC dosages).", "study_duration": "Median 35.5 months (IQR 24.3-36.5).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:55.055631+00:00"}
{"study_id": 104871, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the prevalence and predictors of NAFLD and its histological high-risk components, including the role of alanine aminotransferase (ALT), in morbidly obese Indians undergoing bariatric surgery.", "results_summary": "Elevated ALT independently predicted NAFLD and was significantly associated with NASH and fibrosis. The study found no complications related to liver biopsy, but did not assess alanine's safety or efficacy as a supplement.", "population_specificity": "Morbidly obese Indian patients undergoing bariatric surgery (n=134).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:57.358456+00:00"}
{"study_id": 104872, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of brain metabolites, including alanine, in the murine model of cerebral malaria to understand disease pathogenesis and treatment monitoring.", "results_summary": "The study found increased alanine concentrations in the brain, indicating brain ischemia in experimental cerebral malaria. Lowering lactate levels improved survival, but alanine's direct therapeutic role was not explored.", "population_specificity": "Mice infected with Plasmodium Berghei (PbA) ANKA strain to mimic human cerebral malaria.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:57.712561+00:00"}
{"study_id": 104870, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The study aimed to determine the aetiology, clinical presentation, and predictors of survival in Budd Chiari Syndrome patients, with incidental mention of serum alanine transaminase levels as a predictor of poor survival.", "results_summary": "The study found that elevated serum alanine transaminase (> 40 U/L) was associated with poor survival in Budd Chiari Syndrome patients (p < 0.005), but did not evaluate alanine as a supplement or therapeutic agent.", "population_specificity": "Budd Chiari Syndrome patients (n=25, age range 2-50 years, mean 14.7 \u00b1 12.41 years, 64% pediatric, 64% male).", "effective_dosage": "Not available", "study_duration": "Not applicable (observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:57.758146+00:00"}
{"study_id": 104873, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to develop a model-based dosing algorithm for busulfan, incorporating alanine transferase as a covariate on clearance, to optimize dosing and sampling for stem cell transplantation patients.", "results_summary": "The study found that busulfan exposure was best predicted when adjusted ideal body weight and alanine transferase were included as covariates on clearance. A sparse sampling scheme with five samples per patient was sufficient to characterize busulfan pharmacokinetics.", "population_specificity": "Stem cell transplantation patients (n = 29).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:43:59.190821+00:00"}
{"study_id": 104875, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify non-invasive metabolic biomarkers, including alanine-related metabolites, to monitor treatment response in pediatric NAFLD patients.", "results_summary": "The study found that VSL#3 treatment altered urinary metabolic profiles, including changes in amino-acid metabolism (e.g., tyrosine and BAIBA), which correlated with clinical endpoints like alanine aminotransferase and BMI.", "population_specificity": "31 pediatric NAFLD patients enrolled in a VSL#3 clinical trial.", "effective_dosage": "Not specified", "study_duration": "4 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:01.075699+00:00"}
{"study_id": 104874, "supplement_id": 863, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the long-term efficacy and safety of tenofovir DF in nucleos(t)ide-naive, HBeAg-positive chronic hepatitis B patients, including monitoring alanine aminotransferase (ALT) levels.", "results_summary": "Tenofovir DF demonstrated potent, continuous viral suppression with increasing HBeAg loss, normalized ALT levels, and good renal safety. However, HBsAg loss was not observed in any patients.", "population_specificity": "Nucleos(t)ide-naive, HBeAg-positive chronic hepatitis B patients (31 participants, 11 females, 20 males, mean age 37.6 \u00b1 9.4 years).", "effective_dosage": "245 mg tenofovir DF per diem.", "study_duration": "96 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:02.864439+00:00"}
{"study_id": 104878, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not assess Alanine; it evaluates the efficacy and safety of nivolumab versus chemotherapy in advanced melanoma patients.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with advanced melanoma who progressed after ipilimumab or ipilimumab and a BRAF inhibitor.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:03.428626+00:00"}
{"study_id": 104877, "supplement_id": 863, "safety_score": "90", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effect of Aloe vera gel extract on plasma total antioxidant capacity (TAC) and oral pathogenic bacteria in healthy volunteers, including its impact on biochemical markers such as alanine transaminase (ALT).", "results_summary": "The study found that Aloe vera gel extract significantly increased plasma TAC and reduced Lactobacillus spp. without significant changes in ALT or other major biochemical markers, and no reported side effects.", "population_specificity": "53 healthy volunteers without allergies, systemic diseases, or current medications.", "effective_dosage": "250 mL daily", "study_duration": "14 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:04.028067+00:00"}
{"study_id": 104880, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the effect of first-line doxorubicin and trabectedin combination on disease control and survival in metastatic leiomyosarcoma, not specifically focused on Alanine.", "results_summary": "The study reported increased alanine aminotransferase concentration as a common adverse event but did not evaluate Alanine's effects or efficacy.", "population_specificity": "Adults (18-70 years) with metastatic or unresectable uterine or soft-tissue leiomyosarcoma.", "effective_dosage": "Not applicable (study did not focus on Alanine supplementation).", "study_duration": "Up to six cycles, each cycle lasting 3 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:05.610482+00:00"}
{"study_id": 104879, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to assess the efficacy and safety of trabectedin, not Alanine, as second-line therapy for patients with advanced translocation-related sarcoma.", "results_summary": "The study found that trabectedin significantly improved progression-free survival compared to best supportive care, but it did not evaluate Alanine's effects.", "population_specificity": "Patients with advanced translocation-related sarcoma, aged 19 or older, unresponsive or intolerant to standard chemotherapy.", "effective_dosage": "Not applicable (study focused on trabectedin, not Alanine).", "study_duration": "Not applicable (study focused on trabectedin, not Alanine).", "interactions": "None mentioned (study focused on trabectedin, not Alanine).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:06.083526+00:00"}
{"study_id": 104881, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to develop a population pharmacokinetic-pharmacodynamic model for leuprolide acetate in prostate cancer patients, not specifically to study alanine.", "results_summary": "The study characterized the pharmacokinetics of leuprolide acetate and its relationship with serum testosterone levels, but did not report specific findings related to alanine.", "population_specificity": "Healthy male volunteers and prostate cancer patients", "effective_dosage": "1 mg intravenous (immediate-release) and 45 mg intramuscular (depot formulation)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:06.569645+00:00"}
{"study_id": 104882, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of trabectedin and docetaxel combination therapy in patients with advanced malignancies, not specifically Alanine.", "results_summary": "The study found dose-limiting toxicities including elevated alanine aminotransferase (ALT) and fatigue, with common adverse events being nausea, fatigue, and neutropenia. One patient achieved a complete response, and 30 had stable disease, with 11 maintaining it for \u22656 months.", "population_specificity": "Patients with advanced malignancies, both with limited and unlimited prior chemotherapy.", "effective_dosage": "Trabectedin (0.4-1.3 mg/m\u00b2) and docetaxel (60 or 75 mg/m\u00b2) in a 21-day cycle.", "study_duration": "Median of four cycles (approximately 84 days).", "interactions": "None mentioned for Alanine specifically.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:10.996461+00:00"}
{"study_id": 104885, "supplement_id": 863, "safety_score": "80", "efficacy_score": 60, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of SAMe in treating chronic liver disease, including its impact on liver function markers such as alanine transaminase (ALT).", "results_summary": "The study found no significant differences in ALT levels between SAMe and placebo groups, suggesting limited efficacy for ALT improvement. SAMe demonstrated safety but had limited clinical value compared to other treatments like UDCA and SNMC in certain chronic liver diseases.", "population_specificity": "705 patients with chronic liver disease, including gravidas and children.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:11.817046+00:00"}
{"study_id": 104884, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the impact of Ascorbic Acid (AA) on inflammatory status in Brain-Dead Donors (BDDs) and its effect on liver function markers, including Alanine Aminotransferase (ALT).", "results_summary": "AA treatment significantly reduced IL-6 mRNA expression and serum levels, and improved liver function markers (AST, ALT) in transplant recipients, suggesting beneficial effects on inflammatory status and graft function.", "population_specificity": "Brain-Dead Donors (BDDs) and liver transplant recipients.", "effective_dosage": "100 mg/kg AA infusion 6 hours before donor operation, followed by 100 mg/kg every 6 hours until organ removal.", "study_duration": "From 6 hours before donor surgery until organ removal (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:12.756991+00:00"}
{"study_id": 104883, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to investigate the impact of baseline cirrhosis status on virologic, serologic, and histologic outcomes in chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF), including effects on alanine aminotransferase levels.", "results_summary": "After 5 years of TDF treatment, 79.7% of cirrhotic and 81.9% of non-cirrhotic patients achieved normal serum alanine aminotransferase levels, with no significant difference between groups (p = 0.586). The study demonstrated favorable virologic, serologic, and histologic outcomes regardless of baseline cirrhosis status.", "population_specificity": "Chronic hepatitis B (CHB) patients with and without baseline cirrhosis, including both HBeAg-positive and HBeAg-negative individuals.", "effective_dosage": "Not specified", "study_duration": "5 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:12.875721+00:00"}
{"study_id": 104876, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the relevance of prognostic markers, including alanine transaminase (ALT), for assessing disease progression in NAFLD, rather than focusing on diagnostic accuracy.", "results_summary": "The abstract suggests that simple criteria, such as ALT ratio > 0.8, may be as effective as more sophisticated biomarker panels for prognostic purposes in NAFLD, though liver biopsy remains the gold standard despite its questionable benefit.", "population_specificity": "Patients with NAFLD, including those with diabetes, metabolic syndrome, obesity, obstructive sleep apnea, or elevated ALT and/or ultrasonological evidence of fatty liver.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:13.258996+00:00"}
{"study_id": 104886, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to compare the effectiveness and safety of peginterferon alfa-2a and peginterferon alfa-2b, both combined with ribavirin, in treating HCV infection, including monitoring alanine aminotransferase levels as part of liver function assessment.", "results_summary": "The study found similar sustained virological response rates (38% overall) and adverse event frequencies between peginterferon alfa-2a and peginterferon alfa-2b groups, with no significant differences in relapse or non-response rates. Alanine aminotransferase levels were monitored but not highlighted as a primary outcome.", "population_specificity": "Chronic HCV-infected patients in Mexico City.", "effective_dosage": "Not specified for alanine; peginterferon and ribavirin dosages not detailed in abstract.", "study_duration": "Treatment duration included assessments up to 48 weeks and 6 months post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:15.883086+00:00"}
{"study_id": 104887, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether omega-3 fatty acid supplementation could reduce alanine aminotransferase (ALT) levels and improve liver health in children with NAFLD.", "results_summary": "Omega-3 supplementation did not significantly reduce ALT levels or liver steatosis but showed modest improvements in aspartate aminotransferase and gamma-glutamyl transpeptidase levels compared to placebo. Adiponectin levels were also higher in the omega-3 group.", "population_specificity": "Overweight/obese children (median age 13 years) with NAFLD diagnosed by elevated ALT and liver hyperechogenicity.", "effective_dosage": "450-1300 mg/day of docosahexaenoic acid and eicosapentaenoic acid.", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:16.135142+00:00"}
{"study_id": 104888, "supplement_id": 863, "safety_score": "70", "efficacy_score": null, "quality_score": 80, "study_goal": "The researchers aimed to assess the tolerability and pharmacokinetics of Erigerontis hydroxybenzenes injection (EHI), a phenolic compound-enriched extract from Erigeron breviscapus, in healthy volunteers, including monitoring for adverse effects such as changes in alanine aminotransferase levels.", "results_summary": "The study found that intravenous EHI was generally tolerated, with the main limitations being transient ECG changes and mild, transient increases in alanine aminotransferase. The tolerated dose was 6 vials (90 mg bioactive phenolic compounds).", "population_specificity": "Healthy Chinese volunteers (40 for tolerability, 10 for pharmacokinetics).", "effective_dosage": "6 vials (equivalent to 90 mg bioactive phenolic compounds), single or once daily for 7 days.", "study_duration": "Single-dose or 7-day multiple-dose administration.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:16.162617+00:00"}
{"study_id": 104889, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate potential relationships between alanine and gene expression profiles (ACAN, COL2A1, MMP13) in osteoarthritis (OA) cartilage to understand its role as a biomarker for collagen degradation.", "results_summary": "Alanine was detected in 15 of 30 OA cartilage samples, indicating its presence when collagen degradation occurs. The study suggests HRMAS NMR spectroscopy can uniquely measure localized collagenous degeneration in OA cartilage via alanine detection.", "population_specificity": "Five subjects undergoing total knee arthroplasty for OA treatment.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:18.594942+00:00"}
{"study_id": 104893, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare the activity of alanine amino transferase (ALT) in saliva between patients with anorexia nervosa and healthy controls.", "results_summary": "The study found that ALT activity in saliva was measured but did not report significant differences between anorexic patients and healthy controls. The focus was primarily on other enzymes like collagenase and AST.", "population_specificity": "28 patients with anorexia nervosa and 38 matched healthy controls.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:20.741599+00:00"}
{"study_id": 104890, "supplement_id": 863, "safety_score": "100", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy versus continuing lamivudine (LAM) plus adefovir (ADV) in LAM-resistant chronic hepatitis B (CHB) patients with a suboptimal response to LAM plus ADV.", "results_summary": "Switching to TDF monotherapy resulted in significantly higher rates of complete virological response (CVR) and alanine aminotransferase normalization compared to continuing LAM plus ADV, with no drug-related adverse effects reported in either group.", "population_specificity": "LAM-resistant chronic hepatitis B (CHB) patients with a suboptimal response to LAM plus ADV.", "effective_dosage": "TDF (300 mg/d orally), LAM (100 mg/d orally), ADV (10 mg/d orally).", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:22.327432+00:00"}
{"study_id": 104892, "supplement_id": 863, "safety_score": "70", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the clinical efficacy, side effects, and laboratory changes (including alanine transaminase, ALT) between single versus twice daily doses of oral isotretinoin for acne vulgaris.", "results_summary": "Both dosing regimens showed significant clinical improvement in acne with no major difference in efficacy, but twice daily dosing resulted in fewer side effects. Mild, clinically insignificant rises in ALT, AST, cholesterol, and triglycerides were observed, with triglycerides more elevated in the twice-daily group.", "population_specificity": "58 patients with acne vulgaris, divided into once-daily (26 patients) and twice-daily (32 patients) dosing groups.", "effective_dosage": "Once daily versus twice daily oral isotretinoin (specific dosage not stated).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:23.020731+00:00"}
{"study_id": 104891, "supplement_id": 863, "safety_score": "30", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers were evaluating the safety and efficacy of ceritinib in patients with ALK-positive, metastatic NSCLC who had progressed on or were intolerant to crizotinib, with a focus on adverse reactions including increased alanine transaminase levels.", "results_summary": "The study found that ceritinib had an objective response rate of 44% and a median duration of response of 7.1 months, but common adverse reactions included increased alanine transaminase (80%), diarrhea (86%), and nausea (80%). Despite frequent dose reductions or interruptions (74%), discontinuation due to adverse reactions was low (10%).", "population_specificity": "Patients with metastatic ALK-positive NSCLC who had disease progression on or intolerance to crizotinib.", "effective_dosage": "750 mg orally once daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:23.983746+00:00"}
{"study_id": 104895, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the impact of phlebotomy on laboratory values and the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C, including the role of alanine aminotransferase (ALT) levels.", "results_summary": "Phlebotomy significantly reduced mean AST and ALT levels over five years and lowered HCC incidence (10.3% vs. 43.7%) compared to non-phlebotomized patients. The protective effect was stronger in patients with normal baseline ferritin levels.", "population_specificity": "Patients with chronic hepatitis C, some previously treated with interferon.", "effective_dosage": "Not specified for alanine (study focused on phlebotomy and other treatments).", "study_duration": "8-year observation period (intervention duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:25.657300+00:00"}
{"study_id": 104894, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to develop a risk prediction model for MTX intolerance in juvenile idiopathic arthritis (JIA) patients, including alanine aminotransferase as one of the predictors.", "results_summary": "The study found that alanine aminotransferase was one of the predictors in the model for MTX intolerance, but the abstract does not detail its specific effects or role in the outcome. The model showed moderate predictive power for MTX intolerance.", "population_specificity": "Juvenile idiopathic arthritis (JIA) patients starting MTX treatment.", "effective_dosage": "Not specified for alanine.", "study_duration": "First year of MTX treatment.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:25.830824+00:00"}
{"study_id": 104896, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate whether endoscopic nasobiliary drainage (ENBD) catheter placement is necessary after common bile duct (CBD) stone clearance, comparing outcomes with and without ENBD across different procedural subgroups.", "results_summary": "The study found no significant differences in post-ERCP complications, CRP normalization, or liver enzyme levels (including ALT) between ENBD and non-ENBD groups overall. However, ENBD was beneficial in reducing post-ERCP pancreatitis and hyperamylasemia specifically in patients who underwent endoscopic papillary balloon dilatation (EPBD).", "population_specificity": "218 patients (139 males, 79 females) with an average age of 60.1\u00b110.8 years who underwent CBD stone removal.", "effective_dosage": "Not applicable", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:26.318434+00:00"}
{"study_id": 104898, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not evaluate Alanine; it focuses on the efficacy and safety of sarilumab in combination with methotrexate for rheumatoid arthritis.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Adults with moderate-to-severe rheumatoid arthritis and inadequate response to methotrexate.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:27.472157+00:00"}
{"study_id": 104897, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of transjugular intrahepatic portosystemic shunt (TIPS) and angioplasty in treating severe jaundice secondary to acute Budd-Chiari syndrome (BCS), including the impact on alanine aminotransferase (ALT) levels.", "results_summary": "The study found that both TIPS and angioplasty significantly reduced ALT levels in patients with acute BCS, with faster improvement in liver function compared to bilirubin levels. No recurrence of jaundice was observed after a mean follow-up of 12.6 months.", "population_specificity": "37 patients with severe jaundice secondary to acute Budd-Chiari syndrome (BCS).", "effective_dosage": "Not available", "study_duration": "Follow-up of 12.6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:28.488307+00:00"}
{"study_id": 104900, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to illustrate the serendipitous development of antiviral drugs, including polyethylene alanine (PEA), and their repurposing for different therapeutic applications.", "results_summary": "The abstract mentions polyethylene alanine (PEA) was initially designed as an antiviral agent but later emerged as a depilatory agent, with no specific results on its efficacy or safety provided.", "population_specificity": "Not specified", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:30.454317+00:00"}
{"study_id": 104899, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers sought to determine the association between thrombopoietin (TPO) level, immature platelet fraction (IPF), immunoglobulin G (IgG) level, spleen size, and platelet count in chronic hepatitis C (CHC).", "results_summary": "The study found that platelet count in CHC was significantly associated with fibrosis, TPO level, IPF, and spleen size, challenging the proposed mechanism of decreased TPO levels or decreased bone marrow production of platelets as a cause of thrombocytopenia.", "population_specificity": "Patients with chronic hepatitis C (CHC) enrolled in an observational study at a referral-based research center.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:31.052747+00:00"}
{"study_id": 104901, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the potential neuroprotective effects of DPP4 inhibitors, which cleave peptides with alanine as the second residue, in the context of neurodegenerative diseases.", "results_summary": "The abstract suggests that DPP4 inhibitors, which act on peptides including those with alanine, may have neuroprotective properties, but the precise mechanisms remain unclear. No direct results on alanine itself are provided.", "population_specificity": "Cell cultures and animal models (no human trials mentioned).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:31.562534+00:00"}
{"study_id": 104903, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the prevalence of YMDD mutations in CHB patients and evaluate the efficacy of lamivudine treatment.", "results_summary": "YMDD mutations were detected in 22.71% of CHB patients, with HBV DNA levels and HBeAg status associated with these mutations. Lamivudine treatment showed no significant difference in ALT normalization or HBV DNA nondetection between patients with and without YMDD mutations, but virological breakthrough was more common in those with mutations.", "population_specificity": "1268 chronic hepatitis B (CHB) patients from outpatient and inpatient departments of six centers.", "effective_dosage": "Not specified", "study_duration": "48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:34.337064+00:00"}
{"study_id": 104904, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of early versus deferred antiretroviral therapy (ART) on liver fibrosis progression in HIV-positive individuals, with a focus on factors like alanine aminotransferase (ALT) levels.", "results_summary": "Higher ALT levels were associated with increased liver fibrosis, as measured by transient elastography (TE), but the study did not evaluate alanine's direct effects or efficacy as a supplement.", "population_specificity": "HIV-positive individuals, including those with hepatitis B or C coinfection (11.5% of participants).", "effective_dosage": "Not available", "study_duration": "Not specified (baseline assessment only)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:34.343691+00:00"}
{"study_id": 104905, "supplement_id": 863, "safety_score": "85", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety, clinical benefits, and quality of life improvements of Viron, an herbal formulation containing Alanine, in patients with chronic hepatitis C virus infection.", "results_summary": "The highest dose of Viron showed a 10% complete virological response and improved alanine aminotransferase levels and quality of life scores, with no serious adverse effects reported. Lower doses were significantly less effective.", "population_specificity": "Patients with chronic hepatitis C virus infection (82 participants).", "effective_dosage": "One, two, or three tablets twice daily.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.253289+00:00"}
{"study_id": 104902, "supplement_id": 863, "safety_score": "20", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TAS266, a novel DR5-targeting Nanobody(\u00ae), in patients with advanced solid tumors.", "results_summary": "TAS266 caused significant but reversible hepatotoxicity, with grade \u22653 liver enzyme elevations in three of four patients at the 3 mg/kg dose, leading to early study termination. Immunogenicity to TAS266 was observed in patients experiencing toxicity, suggesting a potential mechanism for the adverse effects.", "population_specificity": "Adult patients with advanced solid tumors.", "effective_dosage": "3, 10, 15, or 20 mg/kg intravenously on days 1, 8, 15, and 22 of a 28-day cycle.", "study_duration": "28-day treatment cycle (study terminated early due to toxicity).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:35.842161+00:00"}
{"study_id": 104906, "supplement_id": 863, "safety_score": "90", "efficacy_score": 85, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-438 (vonoprazan) in healthy Japanese and non-Japanese men.", "results_summary": "TAK-438 showed rapid absorption, dose-dependent acid suppression, and was well tolerated with no serious adverse events. Mean 24-h intragastric pH>4 holding time ratio was high (100% in Japan, 93.2% in UK at 40 mg dose).", "population_specificity": "Healthy Japanese (N=60) and non-Japanese (UK, N=48) men.", "effective_dosage": "10-40 mg once daily.", "study_duration": "7 consecutive days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.291443+00:00"}
{"study_id": 104908, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study does not address Alanine; it investigates the efficacy and safety of gefitinib combined with bevacizumab in patients with advanced NSCLC harboring EGFR gene mutations.", "results_summary": "The study does not report findings related to Alanine.", "population_specificity": "Patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR gene mutations.", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:37.936334+00:00"}
{"study_id": 104909, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to improve the stability of a therapeutic peptide (DPT-C9h) by modifying its sequence, including replacing arginine 8 with alanine, and assess its functional activity and biodistribution.", "results_summary": "The alanine-modified peptide (Mut3DPT-C9h) showed enhanced stability while retaining functional activity and demonstrated higher tumor accumulation compared to the parental peptide.", "population_specificity": "Preclinical (not specified if in vitro, animal models, or other).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:39.864154+00:00"}
{"study_id": 104907, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety and efficacy of entospletinib, a selective spleen tyrosine kinase inhibitor, in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, including its impact on alanine aminotransferase levels.", "results_summary": "The study found that entospletinib demonstrated clinical activity in CLL, with a 70.1% progression-free survival rate at 24 weeks and a 61.0% objective response rate. Reversible alanine aminotransferase/aspartate aminotransferase elevations occurred in 13.4% of subjects, indicating some liver-related toxicity.", "population_specificity": "Subjects with relapsed or refractory chronic lymphocytic leukemia (n = 41) or non-Hodgkin lymphoma (n = 145).", "effective_dosage": "800 mg twice daily.", "study_duration": "Not explicitly stated in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:40.567669+00:00"}
{"study_id": 104910, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare the efficacy and safety of telbivudine (TBV) and lamivudine (LAM) in normalizing serum alanine aminotransferase (ALT) levels in patients with chronic hepatitis B (CHB).", "results_summary": "Both TBV and LAM significantly reduced ALT levels post-treatment, with TBV showing a greater reduction compared to LAM. The study concluded that TBV may be a better choice due to its lower rates of drug resistance.", "population_specificity": "Patients with chronic hepatitis B (CHB) (TBV n = 202; LAM n = 208).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:42.613272+00:00"}
{"study_id": 104911, "supplement_id": 863, "safety_score": "85", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety and efficacy of deferasirox in reducing iron burden in patients with hereditary hemochromatosis refractory to or intolerant of phlebotomy.", "results_summary": "The study found significant reductions in serum ferritin, transferrin saturation, liver iron concentration, and alanine aminotransferase levels after 12 months of deferasirox treatment. Adverse events were mild and transient, with no significant safety concerns reported.", "population_specificity": "Patients with hereditary hemochromatosis and iron overload refractory to or intolerant of phlebotomy (n=10).", "effective_dosage": "10 \u00b1 5 mg/kg/day", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:42.996496+00:00"}
{"study_id": 104912, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to compare the clinical benefit of continuing trabectedin treatment versus interrupting therapy after six cycles in patients with advanced soft-tissue sarcoma, not specifically to evaluate alanine.", "results_summary": "The study found that continuation of trabectedin improved progression-free survival at 6 months compared to interruption (51.9% vs. 23.1%, p=0.0200). Alanine aminotransferase increases were noted as a toxicity but were not the primary focus.", "population_specificity": "Adult patients with advanced soft-tissue sarcomas previously treated with doxorubicin-based chemotherapy.", "effective_dosage": "Not applicable (study focused on trabectedin, not alanine).", "study_duration": "Median of 11 cycles (range 6-31+) for continuation group.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.376676+00:00"}
{"study_id": 104913, "supplement_id": 863, "safety_score": "70", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of Tripterygium wilfordii Hook F (TwHF) and acitretin in treating moderate to severe psoriasis vulgaris, including effects on alanine transaminase levels.", "results_summary": "The study found no significant difference in efficacy between TwHF and acitretin, but noted a significant increase in alanine transaminase levels in the acitretin group, indicating potential liver-related side effects.", "population_specificity": "Adults with moderate to severe psoriasis vulgaris (PASI score \u2265 10 and psoriasis-affected body surface area \u2265 10%).", "effective_dosage": "Acitretin was administered at 30 mg once daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:44.767996+00:00"}
{"study_id": 104914, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to examine the effects of vildagliptin on hepatic triglyceride levels and insulin sensitivity, including its impact on plasma alanine aminotransferase levels.", "results_summary": "Vildagliptin significantly reduced hepatic triglyceride levels by 27% and lowered plasma alanine aminotransferase levels, with a strong correlation between these reductions. However, it did not affect peripheral insulin sensitivity.", "population_specificity": "Individuals with type 2 diabetes (n = 44) on stable metformin therapy and glycated hemoglobin \u2264 7.6%.", "effective_dosage": "Vildagliptin 50 mg twice daily.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:45.983380+00:00"}
{"study_id": 104915, "supplement_id": 863, "safety_score": "65", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the severity and reversibility of side effects of stanozolol (an anabolic steroid) on liver enzymes (including alanine aminotransferase, ALT/SGPT) and lipid profiles in elderly patients with LDS and venous leg ulcers.", "results_summary": "The study found that stanozolol caused temporary, asymptomatic elevations in liver transaminases (AST/SGOT and ALT/SGPT) and significant decreases in HDL levels, which returned to baseline after discontinuation. No severe adverse effects were reported.", "population_specificity": "Elderly patients with lipodermatosclerosis (LDS) and venous leg ulcers.", "effective_dosage": "2 mg twice daily.", "study_duration": "Up to 6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:46.718535+00:00"}
{"study_id": 104916, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to identify plasma metabolite alterations, including alanine, as potential biomarkers for distinguishing Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI) from normal cognition controls.", "results_summary": "The study found that alanine was one of seven metabolites altered in both AD and aMCI patients, contributing to a logistic regression model that accurately distinguished these groups from controls (AUC 0.918 for AD, 0.826 for aMCI). The panel, including alanine, showed potential diagnostic utility for early-stage AD.", "population_specificity": "Patients with AD (n = 100), aMCI (n = 58), and normal cognition controls (n = 93).", "effective_dosage": "Not specified", "study_duration": "Cross-sectional study (no intervention duration)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:49.510109+00:00"}
{"study_id": 104917, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 82, "study_goal": "The researchers aimed to determine if serum concentrations of alanine transaminase (ALT) and other liver enzymes could predict CYP3A activity, potentially guiding clinical medication adjustments.", "results_summary": "The study found no significant difference in CYP3A activity between patients with normal liver function and moderate fatty liver, but activity was significantly lower in end-stage liver disease patients. ALT and total bilirubin (TB) showed a statistically significant linear relationship with CYP3A activity, suggesting predictive value.", "population_specificity": "45 patients undergoing surgery under general anesthesia, including those with normal liver function, moderate fatty liver, and end-stage liver disease.", "effective_dosage": "Single intravenous dose of 5 mg midazolam.", "study_duration": "Single administration, with CYP3A activity measured 2 hours post-dose.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:50.982713+00:00"}
{"study_id": 104918, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to evaluate drug-drug interactions between the 3D regimen (OBV, PTV/r, DSV) and various medications, including effects on alanine aminotransferase levels.", "results_summary": "Coadministration with ethinyl estradiol-containing contraceptives resulted in elevated alanine aminotransferase levels, while progestin-only contraceptives did not. Most medications showed minimal to modest interactions with the 3D regimen.", "population_specificity": "Healthy volunteers", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Elevated alanine aminotransferase levels with ethinyl estradiol-containing contraceptives; minimal to modest interactions with most medications.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:52.004880+00:00"}
{"study_id": 104922, "supplement_id": 863, "safety_score": "85", "efficacy_score": 78, "quality_score": 88, "study_goal": "The researchers aimed to evaluate the safety of coadministration of ezetimibe with statins, including effects on alanine aminotransferase levels.", "results_summary": "The study found no significant increase in adverse events, including alanine aminotransferase levels > 3 \u00d7 ULN, between ezetimibe-statin combination therapy and statin monotherapy. The incidence of adverse events was similar, supporting the safety of combination therapy.", "population_specificity": "Patients with hypercholesterolaemia at high risk for cardiovascular and cerebrovascular disease (14,856 patients across 20 RCTs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:52.838207+00:00"}
{"study_id": 104921, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to reevaluate the performance of the Pretransplant Assessment of Mortality (PAM) score, including the role of serum alanine aminotransferase, in predicting mortality after allogeneic hematopoietic cell transplantation (HCT).", "results_summary": "The study found that serum alanine aminotransferase was no longer significantly associated with 2-year mortality in the current cohort, unlike in the original study. The revised PAM score was developed to better estimate survival post-HCT, particularly for patients receiving myeloablative conditioning regimens.", "population_specificity": "1549 patients who underwent allogeneic HCT from 2003 through 2009 for hematologic malignancies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:53.368706+00:00"}
{"study_id": 104920, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine whether weight loss contributed significantly to the clinical responses (glycemic control, cardiovascular risk markers, and liver enzymes) observed with exenatide once weekly in patients with type 2 diabetes mellitus.", "results_summary": "The study found that exenatide once weekly improved glycemic parameters (A1C and FPG) and cardiovascular risk markers (systolic BP, LDL-C, total cholesterol, triglycerides) as well as liver enzymes (ALT and AST), with the greatest improvements seen in patients with the most weight loss. Adverse events like gastrointestinal issues and hypoglycemia were more common in the quartile with the greatest weight loss.", "population_specificity": "Patients with type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified (exenatide once weekly).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:53.747936+00:00"}
{"study_id": 104923, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the association between the PNPLA3 gene SNP rs738409 G allele and non-alcoholic fatty liver disease (NAFLD) susceptibility, as well as its impact on serum alanine aminotransferase (ALT) levels in an Asian population.", "results_summary": "The study confirmed the G allele as a strong risk factor for NAFLD (OR = 1.92) and found that G allele carriers had higher serum ALT levels (SMD = 7.03) and higher fibrosis scores (SMD = 0.39).", "population_specificity": "Asian population (4,495 cases and 7,431 controls).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:54.350644+00:00"}
{"study_id": 104924, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers evaluated the feasibility and tolerability of a dose-dense epirubicin-based regimen with paclitaxel in high-risk primary breast cancer patients, including monitoring nonhematologic toxicity such as alanine aminotransferase (ALT) elevation.", "results_summary": "One patient experienced G3 transaminitis (alanine aminotransferase elevation) during the FEC regimen, but no G3 or higher nonhematologic toxicity was observed with paclitaxel. The overall tolerability of the regimen was deemed insufficient for study completion.", "population_specificity": "High-risk primary breast cancer patients (n=11) post-quadrantectomy or modified radical mastectomy.", "effective_dosage": "Not specified for alanine (ALT was monitored as part of toxicity assessment).", "study_duration": "FEC regimen every 14 days for 3 cycles, followed by weekly paclitaxel for 8 cycles.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:57.990713+00:00"}
{"study_id": 104925, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the biochemical features of alanine:glyoxylate aminotransferase (AGT) and the molecular and cellular effects of its mutations in Primary Hyperoxaluria Type I (PH1).", "results_summary": "The study found that AGT mutations, particularly in combination with polymorphic changes and homozygosis or compound heterozygosis, significantly influence the enzymatic phenotype in PH1 patients. These findings help understand genotype/phenotype correlations and inform therapeutic approaches.", "population_specificity": "Patients with Primary Hyperoxaluria Type I (PH1) caused by AGXT gene mutations.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:44:58.059847+00:00"}
{"study_id": 104926, "supplement_id": 863, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the therapeutic effect of Chishaodanpi decoction (CSDPD), which includes Alanine, on chronic viral cholestatic hepatitis compared to standard treatment.", "results_summary": "The treatment group showed significantly better improvements in symptoms and liver function markers (TBil, DBil, TBA, ALP, ALT, AST, \u03b3-GT) compared to the control group, with a total effective rate of 92.6% versus 62.3%. Mild adverse effects like increased bowel movement frequency and stomach-ache were noted in a few patients.", "population_specificity": "107 subjects with chronic viral cholestatic hepatitis.", "effective_dosage": "Modified CSDPD, 100 mL twice a day (Alanine content not specified).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:00.284970+00:00"}
{"study_id": 104927, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to examine the relationship between sarcopenia and elevated aminotransferase activity, particularly focusing on whether sarcopenia is an independent risk factor for elevated liver enzymes in non-obese and non-alcoholic individuals.", "results_summary": "The study found that sarcopenia was significantly associated with elevated aminotransferase levels in men, even after adjusting for confounding factors like BMI, diet, and exercise. However, this correlation was not observed in women after adjusting for BMI.", "population_specificity": "13,431 subjects from the Korean National Health and Nutrition Examinations, including both males and females.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:00.465297+00:00"}
{"study_id": 104928, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine whether ischemic preconditioning (IPC) and anesthetic preconditioning (APC) provided cytoprotection against ischemia-reperfusion injury in liver resection patients using intermittent clamping, with alanine aminotransferase (ALT) as one of the markers assessed.", "results_summary": "The study found no significant differences in ALT levels or other markers of hepatocyte dysfunction, apoptosis, histologic lesions, or postoperative outcomes between the IPC, APC, and control groups, suggesting no additional cytoprotection from these preconditioning strategies.", "population_specificity": "106 patients without underlying liver disease undergoing liver resection with intermittent clamping.", "effective_dosage": "Not specified for alanine (ALT was a marker, not an intervention).", "study_duration": "Preconditioning interventions (IPC: 10 min occlusion/10 min reperfusion; APC: 20 min sevoflurane) before liver transection.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:02.547476+00:00"}
{"study_id": 104929, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine the immune-modifying effects of HLA-DRB1*03:01 and HLA-DRB1*04:01 alleles on autoimmune hepatitis (AIH) severity and clinical characteristics, including alanine transaminase levels.", "results_summary": "The study found no association between HLA alleles and alanine transaminase levels, but HLA-DRB1*03:01 was linked to higher immunoglobulin G levels, and HLA-DRB1*04:01 was associated with older age at presentation and female predominance. HLA-DRB1*03:01-positive patients required immunosuppressive medication and liver transplantation more frequently.", "population_specificity": "649 Dutch patients with type-1 autoimmune hepatitis (AIH).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:02.609249+00:00"}
{"study_id": 104930, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "To evaluate the effectiveness of response-guided add-on therapy with adefovir (ADV) and lamivudine (LAM) in cirrhotic hepatitis B (CHB) patients, focusing on virological response, YMDD mutations, and liver function.", "results_summary": "Early complete virologic response at week 24 was associated with maintained viral suppression and reduced YMDD mutations after 144 weeks. Patients who failed to achieve complete virological response at week 24 saw further HBV DNA reduction with combination therapy, and all arms showed biochemical benefits, including improved alanine aminotransferase and albumin levels.", "population_specificity": "100 patients with CHB and cirrhosis.", "effective_dosage": "Not specified.", "study_duration": "144 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:03.099160+00:00"}
{"study_id": 104931, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The study aimed to assess the effect of abiraterone acetate plus prednisone on overall survival, time to opiate use, and subsequent therapies in chemotherapy-naive castration-resistant prostate cancer patients.", "results_summary": "The study found that abiraterone acetate plus prednisone significantly prolonged overall survival compared to placebo plus prednisone (34.7 vs. 30.3 months, HR 0.81, p=0.0033). Increased alanine aminotransferase was a notable adverse event in the abiraterone acetate group (6% vs. <1% in placebo).", "population_specificity": "Asymptomatic or mildly symptomatic chemotherapy-naive castration-resistant prostate cancer patients.", "effective_dosage": "Abiraterone acetate (1000 mg once daily) plus prednisone (5 mg twice daily).", "study_duration": "Median follow-up of 49.2 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:05.277135+00:00"}
{"study_id": 104932, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety, efficacy, and impact on quality of life of gefitinib in elderly patients with advanced NSCLC harboring an EGFR mutation, not specifically Alanine.", "results_summary": "The study found that gefitinib improved progression-free survival and response rate compared to standard chemotherapy, with elevation of alanine transaminase being a common adverse event. No significant difference in overall survival or quality of life deterioration was observed between treatment groups.", "population_specificity": "Elderly patients (\u226570 years) with advanced NSCLC and an EGFR mutation, performance status 0-2.", "effective_dosage": "Not mentioned", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:06.839420+00:00"}
{"study_id": 104933, "supplement_id": 863, "safety_score": "85", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and safety of human placental extract (HPE) compared to a liver extract and flavin adenine dinucleotide (LE\u2013FAD) mixture in treating alcoholic or nonalcoholic steatohepatitis (ASH or NASH) with elevated alanine aminotransferase (ALT) levels.", "results_summary": "The study found no significant difference in treatment efficacy (defined as \u226520% ALT improvement) between HPE and LE\u2013FAD (62.9% vs. 48.8%, p=0.0772). Adverse drug reactions were minimal to moderate (3.1% occurrence) and similar between groups.", "population_specificity": "Patients with ASH or NASH and serum ALT levels 1.5-fold higher than normal.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:07.987714+00:00"}
{"study_id": 104934, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effect of resveratrol on insulin resistance, glucose, and lipid metabolism in patients with non-alcoholic fatty liver disease.", "results_summary": "Resveratrol significantly improved liver enzyme levels (aspartate aminotransferase, alanine aminotransferase), glucose metabolism, lipid profile, and reduced inflammation markers while increasing adiponectin levels in patients with non-alcoholic fatty liver disease.", "population_specificity": "60 subjects with non-alcoholic fatty liver disease.", "effective_dosage": "2 capsules of 150mg resveratrol twice daily.", "study_duration": "Three months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:08.497276+00:00"}
{"study_id": 104935, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to assess the association between everolimus intake and adverse effects, including elevated alanine aminotransferase (ALT), in patients with solid tumors.", "results_summary": "The meta-analysis found that everolimus significantly increased the risk of elevated ALT (relative risk 2.96, p < 0.003), along with fatigue, hyperglycemia, and hyperlipidemia. The study did not evaluate Alanine's efficacy or safety as a supplement.", "population_specificity": "Patients with solid tumors participating in randomized clinical trials.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:08.500991+00:00"}
{"study_id": 104936, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the influence of HTLV-2 co-infection on hepatic fibrosis and alanine aminotransferase levels in patients co-infected with HIV-1 and HCV.", "results_summary": "HTLV-2-HIV-1-HCV co-infected patients showed lower alanine aminotransferase levels and delayed hepatic fibrosis progression compared to HIV-1-HCV co-infected patients, along with altered immune responses.", "population_specificity": "Patients co-infected with HIV-1 and HCV, with or without HTLV-2.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:10.453001+00:00"}
{"study_id": 104938, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the structural and functional characteristics of marine membrane-active peptides (MAPs), including those with histidino-alanine bridges, and their potential therapeutic applications.", "results_summary": "The study highlights that marine-derived peptides, including those with histidino-alanine modifications, exhibit enhanced stability and bioavailability, making them promising candidates for novel therapeutics and drug-delivery systems. These peptides show potential in addressing antibiotic resistance and membrane perturbation.", "population_specificity": "Marine organisms (not human subjects).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:10.883525+00:00"}
{"study_id": 104937, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical efficacy of a TCM intervention (\"TTK\") for treating liver failure due to chronic hepatitis B, focusing on survival rates and liver function restoration.", "results_summary": "The \"TTK\" group showed significantly lower fatality rates (16.67%) compared to the control groups (51.61% and 35.38%) and improved liver function markers like serum albumin, though no significant changes were observed in alanine transaminase levels.", "population_specificity": "Patients with liver failure due to chronic hepatitis B virus infection (144 participants).", "effective_dosage": "Not specified in the abstract.", "study_duration": "8 weeks of treatment, followed by 48 weeks of follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:11.648234+00:00"}
{"study_id": 104939, "supplement_id": 863, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine the effect of acute alcohol consumption on enterocyte damage, using markers like alanine aminotransferase (ALT) among others, but not specifically to evaluate Alanine itself.", "results_summary": "The study found that acute alcohol consumption caused a significant but temporary increase in enterocyte damage markers (I-FABP, L-FABP), but no significant increase in endotoxemia markers (LBP, sCD14, IL-6). Alanine aminotransferase (ALT) was measured as a hepatocyte damage marker, but results specific to Alanine were not highlighted.", "population_specificity": "15 healthy volunteers", "effective_dosage": "Not specified for Alanine", "study_duration": "One-day intervention (alcohol vs. water) with follow-up measurements over 24 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:14.679045+00:00"}
{"study_id": 107967, "supplement_id": 881, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specify a research goal related to antioxidants.", "results_summary": "The abstract mentions that antioxidants are among the drugs co-prescribed to treat side effects of platinum-based chemotherapy, but it does not report specific findings about their effects.", "population_specificity": "Cancer patients receiving platinum-based chemotherapy.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:21.338991+00:00"}
{"study_id": 107962, "supplement_id": 881, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to explore how dietary antioxidants and nutraceuticals can mitigate cognitive decline in non-pathological brain aging and Alzheimer's disease.", "results_summary": "The study suggests that antioxidants and nutraceuticals can ameliorate cognitive decline by addressing oxidative damage, mitochondrial impairment, and neuroinflammation, though clinical trials are needed to confirm their effectiveness.", "population_specificity": "Elderly individuals experiencing non-pathological brain aging or Alzheimer's disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:45:22.174838+00:00"}
